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Abstract
Background: Change in the prevalence of raised blood pressure could be due to both
shifts in the entire distribution of blood pressure (representing the combined effects of
public health interventions and secular trends) and changes in its high-blood-pressure
tail (representing successful clinical interventions to control blood pressure in the hyper-
tensive population). Our aim was to quantify the contributions of these two phenomena
to the worldwide trends in the prevalence of raised blood pressure.
Methods: We pooled 1018 population-based studies with blood pressure measurements
on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood
pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood
pressure by sex and 10-year age group from 20–29 years to 70–79 years in each study,
taking into account complex survey design and survey sample weights, where rele-
vant. We used a linear mixed effect model to quantify the association between (probit-
transformed) prevalence of raised blood pressure and age-group- and sex-specific
mean blood pressure. We calculated the contributions of change in mean SBP and
DBP, and of change in the prevalence-mean association, to the change in prevalence of
raised blood pressure.
Results: In 2005–16, at the same level of population mean SBP and DBP, men and
women in South Asia and in Central Asia, the Middle East and North Africa would have
the highest prevalence of raised blood pressure, and men and women in the high-
income Asia Pacific and high-income Western regions would have the lowest. In most
region-sex-age groups where the prevalence of raised blood pressure declined, one half
or more of the decline was due to the decline in mean blood pressure. Where prevalence
of raised blood pressure has increased, the change was entirely driven by increasing
mean blood pressure, offset partly by the change in the prevalence-mean association.
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Conclusions: Change in mean blood pressure is the main driver of the worldwide change in
the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the
distribution has also contributed to the change in prevalence, especially in older age groups.
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Introduction
Raised blood pressure, commonly defined as systolic blood
pressure (SBP)  140 mmHg or diastolic blood pressure
(DBP)  90 mmHg, is used to identify individuals at high
risk of cardiovascular diseases.1–5 Globally, one in four
men and one in five women, totalling 1.13 billion adults,
had raised blood pressure in 2015.6 One of the global non-
communicable disease (NCD) targets adopted by the
World Health Organization (WHO) in 2013 is to reduce
the prevalence of raised blood pressure by 25% compared
with its 2010 level, by 2025.7
The prevalence of raised blood pressure varies substan-
tially across and within regions and countries, with age-
standardized adult prevalence in 2015 ranging from 20%
in the high-income Asia Pacific region to 33% in Central
and Eastern Europe for men, and from 11% in the high-
income Asia Pacific region to 28% in sub-Saharan Africa
for women.6 Prevalence has declined substantially in high-
income regions for decades, and is also declining in some
middle-income regions; it has been stable or has increased
in other low- and middle-income regions.6
Blood pressure is a complex trait, affected by genes,
fetal and early childhood nutrition and growth,8 adiposity
and weight gain,9,10 diet (especially sodium and potassium
intakes),9,11,12 alcohol use,10,13 smoking,14 physical activ-
ity,10,15 air pollution,16 lead,17 noise,18 psychosocial
stress,19 sleep duration20 and the use of blood pressure-
lowering medicines. Changes in some of these factors, for
example increase in body mass index (BMI) and better
nutrition in childhood and adolescence, can shift the entire
population distribution of blood pressure, and hence
change its mean as well as the prevalence of raised blood
pressure. In contrast, the use of antihypertensive medicines
and lifestyle change to reduce blood pressure in those with
elevated levels would reduce the prevalence of raised blood
pressure by acting on the high-blood-pressure tail of the
distribution, and hence change the shape of the distribu-
tion with a relatively small impact on its mean. An import-
ant question that can inform strategies for meeting the
global target and reducing the burden of raised blood pres-
sure, is to what extent regional differences and changes
over time in the prevalence of raised blood pressure are
driven by variations in the mean SBP and DBP versus by
the shape of the distribution. We used a database of
population-based studies with global coverage conducted
over three decades to investigate contributions of popula-
tion mean and high-blood-pressure individuals to world-
wide trends and variations in raised blood pressure.
Methods
Study design
We first used population-based data to estimate the associ-
ation between the prevalence of raised blood pressure,
defined as SBP  140 mmHg or DBP  90 mmHg, and
population mean SBP and DBP among men and women
aged 20 to 79 years in nine regions of the world, from
1985 to 2016. We used a linear mixed effect model to
quantify the association between the prevalence of raised
blood pressure and mean blood pressure. Our statistical
model, described below, allowed the prevalence of raised
Key Messages
• After accounting for the difference in mean blood pressure, there is still a 3–5 percentage-point difference in the
prevalence of raised blood pressure across regions, being highest in South Asia and in Central Asia, the Middle East
and North Africa, and lowest in the high-income Asia Pacific and high-income Western regions.
• Shifts in entire distribution of blood pressure have been the main driver of the change in prevalence of raised blood
pressure.
• There is also a measurable contribution from the change in the high-blood-pressure tail of the distribution, towards
lowering the prevalence of raised blood pressure, especially in older people.
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blood pressure at any level of mean SBP and DBP to differ
by age group, region and time period. We then used the fit-
ted association to estimate the contributions of changes in
the population mean blood pressure versus changes in the
shape of its distribution (represented by how the
prevalence-mean association varied over region and time),
to the changes in the prevalence of raised blood pressure in
different regions.
Data sources
We used data from NCD Risk Factor Collaboration (NCD-
RisC) database, which contains studies that had measured
blood pressure in representative samples of the national
populations or of one or more sub-national regions and com-
munities. NCD-RisC is a worldwide network of health re-
searchers and practitioners whose aim is to document
systematically the worldwide trends and variations in NCD
risk factors. Our methods for identifying and accessing data
sources, and the inclusion and exclusion criteria, are
described in recent publications.6,21–24 In summary, the data-
base was collated through multiple routes for identifying and
accessing data. We accessed publicly available population-
based multi-country and national measurement surveys as
well as the WHO STEPwise approach to Surveillance
(STEPS) surveys. We requested, via WHO and its regional
and country offices, ministries of health and other national
health and statistical agencies to identify and access
population-based surveys. Requests were also sent via the
World Heart Federation to its national partners. We made a
similar request to the co-authors of an earlier pooled analysis
of cardiometabolic risk factors,25–28 and invited them to re-
analyse data from their studies and join NCD-RisC. To iden-
tify major sources not accessed through the above routes, we
searched and reviewed published studies, and invited all eli-
gible studies to join NCD-RisC. Finally, NCD-RisC mem-
bers are periodically asked to review the list of sources from
their country, to suggest additional sources currently not in
the database and to verify that the included data from their
country meet the inclusion criteria as listed in the
Supplementary data (available at IJE online) and that there
are no duplicates. Here, we analysed data collected from
1985 to 2016 on men and women aged 20–79 years, in 10-
year age groups from 20–29 years to 70–79 years.
Statistical methods
We first calculated mean SBP, mean DBP and prevalence
of raised blood pressure for these age groups by sex in each
study, taking into account complex survey design and sur-
vey sample weights, where relevant. We excluded data
points which did not cover complete 10-year age groups,
e.g. those in people aged 25–29 years or 60–64 years, to
avoid bias in the estimated associations. We also excluded
age-sex groups with < 25 participants, because their means
and prevalence have larger uncertainty.
We then estimated the relationship between the preva-
lence of raised blood pressure and mean, using a linear mixed
effect model, shown below in the equation (where e is the
error term), separately by sex. We used probit-transformed
prevalence because it provided a better fit to the data than a
simple linear model or logit transformation. The model
included age group (10-year age groups from 20–29 to
70–79) and the decade when the data were collected
(1985–94, 1995–2004 or 2005–16). We also included inter-
actions between age group and mean blood pressure, be-
tween decade and mean blood pressure, and among these
three terms, which allowed the prevalence-mean association
to vary by age group and over time. We included regional
random intercepts to account for the differences in preva-
lence at any level of mean SBP and DBP by region. The re-
gions, used in previous analyses of cardiometabolic risk
factors,6,21–24 were: Central and Eastern Europe; Central
Asia, the Middle East and North Africa; East and South-east
Asia; high-income Asia Pacific; high-income Western coun-
tries; Latin America and the Caribbean; Oceania; South Asia;
and sub-Saharan Africa. Countries in each region are listed in
Supplementary Table 1 (available as Supplementary data at
IJE online). The models were fitted in statistical software R
version 3.4.2. Goodness of fit of the models was assessed by
conditional R2, which represents the proportion of variance
explained by both fixed and random factors.29
Probit-transformed prevalence of raised blood pressure
¼ b0 þ b1MeanSBP þ b2MeanDBP
þ b3Age groupþ b4Decade
þ b5Age group Decadeþ b6MeanSBP  Age group
þ b7MeanDBP  Age group
þ b8MeanSBP Decadeþ b9MeanDBP Decade
þ b10MeanSBP  Age group Decade
þ b11MeanDBP  Age group Decade
þ Random interceptRegion þ e
We used a simulation approach to account for the un-
certainty in the mean and prevalence data used in fitting
the regression. Specifically, we used 1000 draws from the
uncertainty distributions of each age- and sex-specific in-
put data point (i.e. mean SBP and DBP and prevalence of
raised blood pressure) with uncertainty represented by a
normal distribution for mean SBP and DBP and by a bino-
mial distribution for prevalence of raised blood pressure.
We then fitted a separate regression to each of the 1000
simulated datasets. We sampled 1000 draws from the joint
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distribution of the regression coefficients for each of the
1000 fitted regressions (i.e. 1 000 000 sets of regression co-
efficients). We report the median of the resulting 1 000 000
draws for each coefficient, and their 2.5th and 97.5th per-
centiles as the 95% confidence interval. We also report the
median of conditional R2 from the 1000 fitted regressions.
We used the fitted regressions to quantify how much dif-
ferences across regions, and changes over time in the preva-
lence of raised blood pressure, were driven by differences/
changes in mean SBP and DBP, versus by differences/
changes in the prevalence-mean association. We first used
the age-sex-specific global mean SBP and DBP in 2010
(mid-point of the 2005–16 period) in the fitted associ-
ation, and estimated the prevalence of raised blood pressure
by region. The age-sex-specific mean SBP and DBP values
were taken from a recent comprehensive analysis of world-
wide trends in blood pressure,6 and are listed in the
Supplementary Table 2 (available as Supplementary data at
IJE online). We report the differences between the predicted
regional raised blood pressure prevalence and that of the
world as a whole. These differences measure how much
prevalence would vary across regions—due to geographical
variations in the shape of blood pressure distribution—if
they had the same population mean blood pressure.
We then decomposed total change in prevalence of raised
blood pressure from 1985–94 to 2005–16 into contributions
of change in mean SBP and DBP, change in the shape of
prevalence-mean association and interaction of the two. The
contribution of change in mean was estimated by allowing
mean SBP and DBP for each age, sex and region to change
over time, while keeping the decade variable fixed at
1985–94. The contribution of change in association was esti-
mated by setting mean SBP and DBP to their 1990 levels
(mid-year of 1985–94) for each age, sex and region, and
allowing the decade variable to change. The interaction of
the two factors is the difference between total change in
prevalence and the sum of the above two components. The
three components are schematically shown in Figure 1.
We repeated the above analyses for each of the
1 000 000 sets of regression coefficients. We report the me-
dian of the resulting 1 000 000 estimates as our main result
and their 2.5th and 97.5th percentiles as the 95% confi-
dence interval. All analyses were done separately for men
and women. Results were calculated by 10-year age groups
Figure 1. Schematic diagram for the contributions of change in mean blood pressure and in shape of the blood pressure distribution to the change in
prevalence of raised blood pressure. Each S-shaped curve shows what the prevalence of raised blood pressure would be at different levels of popula-
tion mean for a specific shape of population distribution. A change in mean without a change in the shape of the distribution (Panel A) would move
prevalence along a curve (orange point in Panel D). A change in the shape of the distribution without a change in mean (Panel B) would vertically
move prevalence from one curve to another (blue point in Panel D). The combination (Panel C) would move prevalence from one curve to another, as
well as along the curve (purple point in Panel D). The figure shows the contributions when raised blood pressure is defined based on one blood pres-
sure (either SBP or DBP). The same concept applies when raised blood pressure is defined based on both SBP and DBP.
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and then aggregated into two age bands, 20–49 years and
50–79 years, by taking the weighted average of age-specific
results; weights from the WHO standard population were
used.
Results
Data sources
We used data from 1018 population-based studies with
88 559 656 participants, of whom 86 187 860 were aged
20–79 years, and satisfied the above inclusion criteria
(Supplementary Table 3, available as Supplementary data
at IJE online). A total of 385 studies were from the high-
income Western region, 108 from East and South-east Asia,
107 from Central Asia, the Middle East and North Africa,
106 from Central and Eastern Europe, 83 from sub-
Saharan Africa, 79 from Latin America and the Caribbean,
78 from high-income Asia Pacific, 38 from South Asia and
34 from Oceania. The individual-level data were
summarized into 7910 age-sex-specific pairs of mean of
and prevalence of raised blood pressure. The number of
data sources by country is shown in Figure 2, and a list of
data sources and their characteristics is provided in
Supplementary Table 4 (available as Supplementary data at
IJE online).
Association of prevalence of raised blood
pressure with mean SBP and DBP
The coefficients of the regression models are listed in
Supplementary Tables 5 and 6 (available as Supplementary
data at IJE online). Together, mean SBP and DBP, decade, age
group and region explained most of the variation in the preva-
lence of raised blood pressure, evidenced by the high condi-
tional R2 statistics of 0.918 for women and 0.871 for men.
Changes in prevalence of raised blood pressure
and mean SBP and DBP, by region
In 2005–16, the age-standardized prevalence of raised
blood pressure in people aged 20–49 years ranged from
4% (95% credible interval: 3–6%) in high-income Asia
Pacific to 16% (13–19%) in sub-Saharan Africa in women,
and from 14% (11–17%) in high-income Asia Pacific to
25% (21–30%) in Central and Eastern Europe in
men. In those aged 50–79 years, the range was from 31%
Figure 2. Number of blood pressure data sources from 1985 to 2016 used in the analysis, by country.
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(26–36%) in high-income Asia Pacific to 56% (52–61%)
in sub-Saharan Africa in women, and from 40% (36–43%)
in the high-income Western region to 57% (51–63%) in
Central and Eastern Europe in men.
The prevalence of raised blood pressure decreased sub-
stantially from 1985–94 to 2005–16 in the two high-
income regions and Central and Eastern Europe in both
men and women across all ages (Figure 3).6 It also
decreased in Latin America and the Caribbean, and in
Central Asia, the Middle East and North Africa, and mar-
ginally in men in sub-Saharan Africa. Over the same
period, mean SBP and mean DBP decreased in these
regions and sexes, except in men in sub-Saharan Africa,
whose mean SBP and DBP increased, and in men in
Central Asia, the Middle East and North Africa, whose
mean SBP and DBP were unchanged. The prevalence of
raised blood pressure and mean SBP and DBP increased in
Oceania and South Asia.
Contributions of mean and shape of blood
pressure distribution to regional variations in
raised blood pressure
Although in 2005–16 the ranking of regions in terms of
prevalence of raised blood pressure was largely the same as
Figure 3. Changes in prevalence of raised blood pressure, mean SBP and mean DBP from 1985–94 to 2005–16, by region, sex and age group.
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the ranking of the mean, especially for women, inter-
region differences in prevalence were not entirely due to
those of mean blood pressure. Rather, some regions had an
excess prevalence compared with what would be expected
based on their mean, and others a lower prevalence com-
pared with what would be expected based on their mean.
At the same level of population mean SBP and DBP as that
of the world as a whole, men and women in South Asia
and in Central Asia, the Middle East and North Africa
would have the highest prevalence of raised blood pres-
sure, about 1–2 percentage points higher than the
world average in different age groups (Figure 4). In con-
trast, at the same level of population mean SBP and DBP as
that of the world as a whole, high-income Asia Pacific
would have the lowest prevalence, followed by the high-
income Western region, with prevalence about 1–3
percentage points lower than the world average across dif-
ferent age and sex groups, especially among women. The
Figure 4. Regional differences in prevalence of raised blood pressure among men and women aged 20–49 years and 50–79 years in 2005–16 if every
region had the same mean SBP and DBP, equal to the global age-sex-specific mean in 2010. The points show the central estimates and the bars their
95% confidence intervals.
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ordering of regions in terms of excess prevalence was simi-
lar between men and women, except for men in Central
and Eastern Europe whose ranking in terms of excess
prevalence was worse than that of women in the same
region.
Contributions of mean and shape of blood pressure
distribution to trends in raised blood pressure
In most regions where sex and age groups experienced a
decline in the prevalence of raised blood pressure, the de-
cline in mean blood pressure was the main driver of the de-
cline in prevalence (Figure 5). The main exceptions to this
distributional shift were men in sub-Saharan Africa and in
Central Asia, the Middle East and North Africa, whose
mean blood pressure increased or remained unchanged
while prevalence declined slightly. Further, in men in Latin
America and the Caribbean and in Central and Eastern
Europe, change in prevalence-mean association contrib-
uted marginally more to prevalence decline than did the
decline in mean blood pressure. Elsewhere, the decline in
mean blood pressure accounted for 60% or more of the de-
cline in the prevalence of raised blood pressure, with a
larger contribution where mean blood pressure declined
more, typically in high-income regions. Change in the
prevalence-mean association, which represents change in
the high-blood-pressure tail of the distribution, was re-
sponsible for the majority of the remainder of change in
prevalence, and for its entirety among men in sub-Saharan
Africa and in Central Asia, the Middle East and North
Africa. The contribution of change in prevalence-mean as-
sociation was larger in those aged 50–79 years than in
those aged 20–49 years in most regions, especially for
women.
The prevalence of raised blood pressure increased
among men and women in Oceania and South Asia, and
among women in sub-Saharan Africa and men in East and
South-east Asia. The increase was driven entirely by rise in
mean blood pressure, offset partly by the change in the
prevalence-mean association. Prevalence of raised blood
pressure remained largely unchanged among women in
East and South-east Asia, due to opposing effects of
Figure 5. Contributions of change in mean blood pressure, change in prevalence-mean association, and the interaction of the two, to change in preva-
lence of raised blood pressure from 1985–94 to 2005–16 by region, sex and age group.
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increasing mean and the decrease brought by the changes
in prevalence-mean association.
Discussion
We found that the trends and geographical variations in
the prevalence of raised blood pressure are largely driven
by shifts in the distribution of blood pressure in whole
populations, rather than by the shape of the distribution.
There was nonetheless an important contribution from
having fewer high-blood-pressure individuals at the same
level of population mean SBP and DBP over time, espe-
cially in older age groups.
Rose and Day30 and Laaser et al.31 used data from the
Intersalt Study and from population-based studies in
Germany, respectively, and found a strong association be-
tween prevalence of raised blood pressure and its mean, as
we did, but neither analysis had sufficient data to quantify
how the association varied in relation to age, time period or
region as was done here. An analysis of data from the multi-
country MONICA Project32 found that the upper percentiles
of blood pressure distribution changed as much as its mean
in some communities, and by a larger amount in others. The
authors concluded that the decline in blood pressure is
mostly a population phenomenon but there was no detailed
quantification of the contribution, especially in relation to
age, time period or region as was done here with substan-
tially more data. Downward shifts in the whole blood pres-
sure distribution over time have also been reported in a few
high-income countries,33–40 with some studies also finding a
larger decline in the upper tail than in the mean of the blood
pressure distribution, which is consistent with our results.
The strengths of our study include presenting the first
global analysis of how much population mean and high-
blood-pressure individuals have contributed to worldwide
trends and variations in raised blood pressure, using a large
global database with data from different regions and over
time, and using methods that allowed the prevalence-mean
association to vary by sex, age group, time period and re-
gion. Despite using the most comprehensive global collec-
tion of population-based studies to date, some regions had
limited data, especially early in our analysis period. Further,
there have been changes over time in devices used for meas-
uring blood pressure in health surveys, with standard mer-
cury sphygmomanometers replaced by random-zero
sphygmomanometers and more recently digital oscillometric
devices. These changes are unlikely to have affected our re-
gional comparisons, and would only affect prevalence-mean
association over time if they had differential effects at high
versus low blood pressure.
Although we found that changes in the prevalence
of raised blood pressure have been mostly due to
whole-distribution shifts, the behavioural, nutritional and
environmental drivers of this shift remain uncertain. In
high-income countries, the decline in blood pressure has
occurred despite the rise in BMI,21 which is an established
risk factor for high blood pressure, but how the concurrent
and at times larger rise in BMI in low- and middle-income
countries may be affecting blood pressure is unclear. Salt in-
take has declined in China41 and possibly in some high-
income countries,42–44 but has not changed in other coun-
tries where blood pressure has declined.45–49 Similarly,
prevalence of smoking has declined in most high-income
countries and in some middle-income countries but remains
high or is increasing in other low- and middle-income re-
gions.50 Alcohol consumption has also had mixed trends
across countries and regions.51 Other potential population-
wide drivers of the decline in mean blood pressure which
tend to improve with social and economic development in-
clude year-round availability of fruits and vegetables, which
might increase the amount and regularity of their consump-
tion;52 central heating at home and work which would
lower winter blood pressure;53–55 and improvements in
early childhood and adolescent nutrition, as seen in greater
height in successive birth cohorts when they reach adult-
hood.23 A role for such distal determinants with life course
impacts is strengthened by the fact that blood pressure is
also decreasing in adolescents in high-income countries and
possibly some middle-income countries.56–60
Whereas these determinants act to lower mean blood
pressure, better developed health systems are more effect-
ive in identifying and treating high-blood-pressure indi-
viduals, which would change the tail of the distribution
without a major impact on its mean. The role of treat-
ment in reducing the prevalence of high blood pressure
has become increasingly important as clinical guidelines
have lowered the threshold for diagnosing and treating
hypertension, e.g. from having an SBP of 160 mmHg or
DBP of 95 mmHg in the 1970s61 to an SBP of 140 mmHg
or DBP of 90 mmHg,4,62 and to an SBP of 130 mmHg or
DBP of 80 mmHg in the newly released ACC/AHA guide-
lines.3 Over time, regional and international guidelines
for diagnosis and treatment of hypertension, which are
evaluated as cost-effective,2,63,64 have been developed
and a larger share of people with raised blood pressure
are treated in high-income countries33,65–72 and in some
middle-income countries.73–78 Nonetheless, treatment
coverage and effectiveness remain low, especially in low-
income settings.79,80 Further, there have been improve-
ments in effectiveness of treatment over time, leading to
better control of those with hypertension. It may also be
the case that changes in some risk factors, e.g. lower salt
intake, have larger benefits for people whose blood pres-
sure is high compared with those with low blood
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pressure,11 hence changing the high-blood-pressure tail of
the distribution as well as its mean.
Our results demonstrate that changes in blood pressure
both at the population and at the individual level have
contributed to lowering raised blood pressure. What fac-
tors have spurred the former over the past few decades,
however, remain largely unclear, and may be related to
societal changes in nutrition, housing and health systems
arising from social and economic development and
technological progress. They also demonstrate the need
for data that go beyond identifying the causes of low or
high blood pressure, but also help measure how these fac-
tors change over time in worldwide populations. Learning
about these factors would inform programmes that can
help reverse the rise in the prevalence of raised blood
pressure or accelerate its decline in low- and middle-
income nations, where prevalence remains the highest,
more effectively.
Supplementary Data
Supplementary data are available at IJE online.
Funding
This work was supported by the Wellcome Trust [101506/Z/13/Z].
Acknowledgement
We thank WHO country and regional offices and the World Heart
Federation for support in data identification and access.
Contributors
M.E. designed the study and oversaw research. Members of the
Country and Regional Data Group collected and re-analysed data,
and checked pooled data for accuracy of information about their
study and other studies in their country. Members of the Pooled
Analysis and Writing Group collated data, checked all data sources
in consultation with the Country and Regional Data Group, and
prepared results. B.Z. analysed data and prepared results. B.Z. and
M.E. wrote the first draft of the report, with input from other mem-
bers of the Pooled Analysis and Writing Group. Members of the
Country and Regional Data Group commented on draft report. B.Z.
is the guarantor for the paper.
Conflict of interest: M.E. received a charitable grant from the Youth
Health Programme of AstraZeneca, and personal fees from Third
Bridge, Scor and Prudential, outside the submitted work. M.W.
received personal fees from Amgen, outside the submitted work. All
other authors declare no competing financial interests.
References
1. Weber MA, Schiffrin EL, White WB et al. Clinical practice guide-
lines for the management of hypertension in the community: a
statement by the American Society of Hypertension and the
International Society of Hypertension. J Clin Hypertens
(Greenwich) 2014;16:14–26.
2. Olsen MH, Angell SY, Asma S et al. A call to action and a life-
course strategy to address the global burden of raised blood pres-
sure on current and future generations: the Lancet Commission
on hypertension. Lancet 2016;388:2665–712.
3. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AA
PA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
for the prevention, detection, evaluation, and management of
high blood pressure in adults: a report of the American College
of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Hypertension 2017, Nov 13. doi:
10.1161/HYP.0000000000000065.
4. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guide-
lines for the management of arterial hypertension: the Task
Force for the Management of Arterial Hypertension of the
European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219.
5. Sanchez RA, Ayala M, Baglivo H et al. Latin American guidelines
on hypertension. Latin American Expert Group. J Hypertens
2009;27:905–22.
6. NCD Risk Factor Collaboration. Worldwide trends in blood
pressure from 1975 to 2015: a pooled analysis of 1479
population-based measurement studies with 19.1 million partici-
pants. Lancet 2017;389:37–55.
7. World Health Organization. Global Action Plan for the
Prevention and Control of Noncommunicable Diseases 2013-
2020. Geneva: World Health Organization, 2013.
8. Victora CG, Adair L, Fall C et al. Maternal and child undernutri-
tion: consequences for adult health and human capital. Lancet
2008;371:340–57.
9. Sacks FM, Campos H. Dietary therapy in hypertension. N Engl J
Med 2010;362:2102–12.
10. IOM (Institute of Medicine). A Population-Based Policy and
Systems Change Approach to Prevent and Control Hypertension.
Washington DC: The National Academies Press, 2010.
11. He FJ, Li J, Macgregor GA. Effect of longer term modest salt re-
duction on blood pressure: Cochrane systematic review and
meta-analysis of randomised trials. BMJ 2013;346:f1325.
12. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P,
Cappuccio FP. Effect of increased potassium intake on cardio-
vascular risk factors and disease: systematic review and meta-
analyses. BMJ 2013;346:f1378.
13. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM,
Rehm J. The effect of a reduction in alcohol consumption on
blood pressure: a systematic review and meta-analysis. Lancet
Public Health 2017;2:e108–20.
14. Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L.
Cigarette smoking and hypertension. Curr Pharm Des 2010;16:
2518–25.
15. Cornelissen VA, Smart NA. Exercise training for blood pressure:
a systematic review and meta-analysis. J Am Heart Assoc 2013;
2:e004473.
16. Cai Y, Zhang B, Ke W et al. Associations of short-term and
long-term exposure to ambient air pollutants with hyperten-
sion: a systematic review and meta-analysis. Hypertension
2016;68:62–70.
International Journal of Epidemiology, 2018, Vol. 47, No. 3 881
17. Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld
EK, Guallar E. Bone lead levels and blood pressure endpoints: a
meta-analysis. Epidemiology 2008;19:496–504.
18. Munzel T, Gori T, Babisch W, Basner M. Cardiovascular effects
of environmental noise exposure. Eur Heart J 2014;35:829–36.
19. Gasperin D, Netuveli G, Dias-da-Costa JS, Pattussi MP. Effect of
psychological stress on blood pressure increase: a meta-analysis
of cohort studies. Cad Saude Publica 2009;25:715–26.
20. Meng L, Zheng Y, Hui R. The relationship of sleep duration and
insomnia to risk of hypertension incidence: a meta-analysis of
prospective cohort studies. Hypertens Res 2013;36:985–95.
21. NCD Risk Factor Collaboration. Trends in adult body-mass
index in 200 countries from 1975 to 2014: a pooled analysis of
1698 population-based measurement studies with 19.2 million
participants. Lancet 2016;387:1377–96.
22. NCD Risk Factor Collaboration. Worldwide trends in diabetes
since 1980: a pooled analysis of 751 population-based studies
with 4.4 million participants. Lancet 2016;387:1513–30.
23. NCD Risk Factor Collaboration. A century of trends in adult
human height. eLife 2016;5:e13410.
24. NCD Risk Factor Collaboration. Worldwide trends in body-
mass index, underweight, overweight, and obesity from 1975 to
2016: a pooled analysis of 2416 population-based measurement
studies in 128.9 million children, adolescents, and adults. Lancet
2017;390:2627–42.
25. Finucane MM, Stevens GA, Cowan MJ et al. National, regional,
and global trends in body-mass index since 1980: systematic ana-
lysis of health examination surveys and epidemiological studies
with 960 country-years and 9.1 million participants. Lancet
2011;377:557–67.
26. Danaei G, Finucane MM, Lin JK et al. National, regional, and
global trends in systolic blood pressure since 1980: systematic
analysis of health examination surveys and epidemiological stud-
ies with 786 country-years and 54 million participants. Lancet
2011;377:568–77.
27. Danaei G, Finucane MM, Lu Y et al. National, regional, and glo-
bal trends in fasting plasma glucose and diabetes prevalence
since 1980: systematic analysis of health examination surveys
and epidemiological studies with 370 country-years and 2.7 mil-
lion participants. Lancet 2011;378:31–40.
28. Farzadfar F, Finucane MM, Danaei G et al. National, regional,
and global trends in serum total cholesterol since 1980: system-
atic analysis of health examination surveys and epidemiological
studies with 321 country-years and 3.0 million participants.
Lancet 2011;377:578–86.
29. Nakagawa S, Schielzeth H. A general and simple method for ob-
taining R2 from generalized linear mixed-effects models.
Methods Ecol Evol 2013;4:133–42.
30. Rose G, Day S. The population mean predicts the number of de-
viant individuals. BMJ 1990;301:1031–34.
31. Laaser U, Breckenkamp J, Ullrich A, Hoffmann B. Can a decline
in the population means of cardiovascular risk factors reduce the
number of people at risk? J Epidemiol Community Health 2001;
55:179–84.
32. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H,
Kuulasmaa K. Pattern of declining blood pressure across replicate
population surveys of the WHO MONICA project, mid-1980s to
mid-1990s, and the role of medication.BMJ 2006;332:629–35.
33. Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence,
awareness, treatment, and control of hypertension in the adult
US population. Data from the health examination surveys, 1960
to 1991.Hypertension 1995;26:60–69.
34. Goff DC, Howard G, Russell GB, Labarthe DR. Birth cohort evi-
dence of population influences on blood pressure in the United
States, 1887-1994. Ann Epidemiol 2001;11:271–79.
35. Goff DC, Gillespie C, Howard G, Labarthe DR. Is the obesity
epidemic reversing favorable trends in blood pressure? Evidence
from cohorts born between 1890 and 1990 in the United States.
Ann Epidemiol 2012;22:554–61.
36. Kastarinen MJ, Nissinen AM, Vartiainen EA et al. Blood pressure
levels and obesity trends in hypertensive and normotensive Finnish
population from 1982 to 1997. J Hypertens 2000;18:255–62.
37. Ulmer H, Kelleher CC, Fitz-Simon N, Diem G, Concin H.
Secular trends in cardiovascular risk factors: an age-period co-
hort analysis of 6 98 954 health examinations in 1 81 350
Austrian men and women. J Intern Med 2007;261:566–76.
38. Long GH, Simmons RK, Norberg M et al. Temporal shifts in cardio-
vascular risk factor distribution.Am J PrevMed 2014;46:112–21.
39. Hopstock LA, Bonaa KH, Eggen AE et al. Longitudinal and
secular trends in blood pressure among women and men in birth
cohorts born between 1905 and 1977: the Tromso Study 1979 to
2008.Hypertension 2015;66:496–501.
40. Holmen J, Holmen TL, Tverdal A, Holmen OL, Sund ER,
Midthjell K. Blood pressure changes during 22-year of follow-up
in large general population - the HUNT Study, Norway. BMC
Cardiovasc Disord 2016;16:94.
41. Du S, Batis C, Wang H, Zhang B, Zhang J, Popkin BM.
Understanding the patterns and trends of sodium intake, potas-
sium intake, and sodium to potassium ratio and their effect on
hypertension in China. Am J Clin Nutr 2014;99:334–43.
42. He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in
England from 2003 to 2011: its relationship to blood pressure, stroke
and ischaemic heart disease mortality.BMJOpen 2014;4:e004549.
43. Ikeda N, Gakidou E, Hasegawa T, Murray CJ. Understanding
the decline of mean systolic blood pressure in Japan: an analysis
of pooled data from the National Nutrition Survey, 1986-2002.
Bull World Health Organ 2008;86:978–88.
44. Laatikainen T, Pietinen P, Valsta L, Sundvall J, Reinivuo H,
Tuomilehto J. Sodium in the Finnish diet: 20-year trends in urin-
ary sodium excretion among the adult population. Eur J Clin
Nutr 2006;60:965–70.
45. Powles J, Fahimi S, Micha R et al. Global, regional and national
sodium intakes in 1990 and 2010: a systematic analysis of 24 h
urinary sodium excretion and dietary surveys worldwide. BMJ
Open 2013;3:e003733.
46. Bernstein AM, Willett WC. Trends in 24-h urinary sodium ex-
cretion in the United States, 1957-2003: a systematic review. Am
J Clin Nutr 2010;92:1172–80.
47. Lee HS, Duffey KJ, Popkin BM. Sodium and potassium intake
patterns and trends in South Korea. J Hum Hypertens 2013;27:
298–303.
48. Johnson C, Praveen D, Pope A et al. Mean population salt con-
sumption in India: a systematic review. J Hypertens 2017;35:3–9.
49. Sarno F, Claro RM, Levy RB, Bandoni DH, Monteiro CA.
Estimated sodium intake for the Brazilian population, 2008-
2009.Rev Saude Publica 2013;47:571–78.
882 International Journal of Epidemiology, 2018, Vol. 47, No. 3
50. Bilano V, Gilmour S, Moffiet T et al. Global trends and projec-
tions for tobacco use, 1990-2025: an analysis of smoking indica-
tors from the WHO Comprehensive Information Systems for
Tobacco Control. Lancet 2015;385:966–76.
51. World Health Organization. Global Status Report on Alcohol
and Health. Geneva: World Health Organization, 2014.
52. Micha R, Khatibzadeh S, Shi P et al. Global, regional and na-
tional consumption of major food groups in 1990 and 2010: a
systematic analysis including 266 country-specific nutrition sur-
veys worldwide. BMJOpen 2015;5:e008705.
53. Lewington S, Li L, Sherliker P et al. Seasonal variation in blood
pressure and its relationship with outdoor temperature in 10 di-
verse regions of China: the China Kadoorie Biobank. J Hypertens
2012;30:1383–91.
54. Saeki K, Obayashi K, Iwamoto J et al. Influence of room heating
on ambulatory blood pressure in winter: a randomised con-
trolled study. J Epidemiol Community Health 2013;67:484–90.
55. Wang Q, Li C, Guo Y et al. Environmental ambient temperature
and blood pressure in adults: a systematic review and meta-ana-
lysis. Sci Total Environ 2017;575:276–86.
56. McCarron P, Davey Smith G, Okasha M. Secular changes in
blood pressure in childhood, adolescence and young adulthood:
systematic review of trends from 1948 to 1998. J Hum
Hypertens 2002;16:677–89.
57. Dong B, Wang Z, Song Y, Wang HJ, Ma J. Understanding trends
in blood pressure and their associations with body mass index in
Chinese children, from 1985 to 2010: a cross-sectional observa-
tional study. BMJOpen 2015;5:e009050.
58. Khang YH, Lynch JW. Exploring determinants of secular de-
creases in childhood blood pressure and hypertension.
Circulation 2011;124:397–405.
59. Chiolero A, Paradis G, Madeleine G, Hanley JA, Paccaud F,
Bovet P. Discordant secular trends in elevated blood pressure
and obesity in children and adolescents in a rapidly developing
country.Circulation 2009;119:558–65.
60. Xi B, Zhang T, Zhang M et al. Trends in elevated blood pressure
among US children and adolescents: 1999-2012. Am J Hypertens
2016;29:217–25.
61. Report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure. A coopera-
tive study. JAMA 1977;237:255–61.
62. Chobanian A, Bakris G, Black H et al. The seventh report of the
Joint National Committee on prevention, detection, evaluation,
and treatment of high blood pressure: the JNC 7 report. JAMA
2003;289:2560–72.
63. Moran AE, Odden MC, Thanataveerat A et al. Cost-effective-
ness of hypertension therapy according to 2014 guidelines.
NEngl J Med 2015;372:447–55.
64. NICE. Hypertension: the Clinical Management of Primary
Hypertension in Adults: Update of Clinical Guidelines 18 and
34. London: National Institute for Health and Care Excellence,
2011.
65. Egan BM, Zhao Y, Axon RN. US trends in prevalence, aware-
ness, treatment, and control of hypertension, 1988-2008. JAMA
2010;303:2043–50.
66. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U.
Hypertension prevalence, awareness, treatment and control in
Germany 1998 and 2008-11. J Hum Hypertens 2015;29:
247–53.
67. Reklaitiene R, Tamosiunas A, Virviciute D, Baceviciene M,
Luksiene D. Trends in prevalence, awareness, treatment, and
control of hypertension, and the risk of mortality among middle-
aged Lithuanian urban population in 1983-2009. BMC
Cardiovasc Disord 2012;12:68.
68. McAlister FA, Wilkins K, Joffres M et al. Changes in the rates of
awareness, treatment and control of hypertension in Canada
over the past two decades. CMAJ 2011;183:1007–13.
69. Cifkova R, Skodova Z, Bruthans J et al. Longitudinal trends in
major cardiovascular risk factors in the Czech population be-
tween 1985 and 2007/8. Czech MONICA and Czech post-
MONICA. Atherosclerosis 2010;211:676–81.
70. Kastarinen M, Antikainen R, Peltonen M et al. Prevalence,
awareness and treatment of hypertension in Finland during
1982-2007. J Hypertens 2009;27:1552–59.
71. Torma E, Carlberg B, Eriksson M, Jansson JH, Eliasson M. Long
term trends in control of hypertension in the Northern Sweden
MONICA study 1986-2009. BMC Public Health 2015;15:957.
72. Sans S, Paluzie G, Balana L, Puig T, Balaguer-Vintro I. Trends in
prevalence, awareness, treatment and control of arterial hyper-
tension between 1986 and 1996: the MONICA-Catalonia study.
Med Clin (Barc) 2001;117:246–53.
73. Fasce E, Campos I, Ibanez P et al. Trends in prevalence, aware-
ness, treatment and control of hypertension in urban commun-
ities in Chile. J Hypertens 2007;25:1807–11.
74. Sengul S, Akpolat T, Erdem Y et al. Changes in hypertension
prevalence, awareness, treatment, and control rates in Turkey
from 2003 to 2012. J Hypertens 2016;34:1208–17.
75. Hou Z, Meng Q, Zhang Y. Hypertension prevalence, awareness,
treatment, and control following China’s healthcare reform. Am
J Hypertens 2016;29:428–31.
76. Dorobantu M, Darabont R, Ghiorghe S et al. Hypertension
prevalence and control in Romania at a seven-year interval.
Comparison of SEPHAR I and II surveys. J Hypertens 2014;32:
39–47.
77. Xi B, Liang Y, Reilly KH, Wang Q, Hu Y, Tang W. Trends in
prevalence, awareness, treatment, and control of hypertension
among Chinese adults 1991-2009. Int J Cardiol 2012;158:
326–29.
78. Pilav A, Doder V, Brankovic S. Awareness, treatment, and con-
trol of hypertension among adult population in the Federation of
Bosnia and Herzegovina over the past decade. J Public Health
Res 2014;3:323.
79. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness,
treatment, and control of hypertension in rural and urban com-
munities in high-, middle-, and low-income countries. JAMA
2013;310:959–68.
80. Mills KT, Bundy JD, Kelly TN et al. Global disparities of hyper-
tension prevalence and control: a systematic analysis of
population-based studies from 90 countries. Circulation 2016;
134:441–50.
International Journal of Epidemiology, 2018, Vol. 47, No. 3 883
NCD Risk Factor Collaboration (NCD-RisC)
Pooled Analysis and Writing
Bin Zhou (Imperial College London, UK); James
Bentham (University of Kent, UK; Imperial College
London, UK); Mariachiara Di Cesare (Middlesex
University, UK); Honor Bixby (Imperial College
London, UK); Goodarz Danaei (Harvard TH Chan
School of Public Health, USA); Kaveh Hajifathalian
(Cleveland Clinic, USA); Cristina Taddei (Imperial
College London, UK); Rodrigo M Carrillo-Larco
(Universidad Peruana Cayetano Heredia, Peru); Shirin
Djalalinia (Tehran University of Medical Sciences,
Iran; Ministry of Health and Medical Education,
Iran); Shahab Khatibzadeh (Brandeis University,
USA); Charles Lugero (Mulago Hospital, Uganda);
Niloofar Peykari (Tehran University of Medical
Sciences, Iran); Wan Zhu Zhang (Uganda Heart
Institute, Uganda); James Bennett (Imperial College
London, UK); Ver Bilano (Imperial College London,
UK); Gretchen A Stevens (World Health
Organization, Switzerland); Melanie J Cowan (World
Health Organization, Switzerland); Leanne M Riley
(World Health Organization, Switzerland);
Zhengming Chen (University of Oxford, UK); Ian R
Hambleton (The University of the West Indies,
Barbados); Rod T Jackson (University of Auckland,
New Zealand); Andre Pascal Kengne (South African
Medical Research Council, South Africa); Young-Ho
Khang (Seoul National University, Republic of
Korea); Avula Laxmaiah (National Institute of
Nutrition, India); Jing Liu (Capital Medical University
Beijing An Zhen Hospital, China); Reza Malekzadeh
(Tehran University of Medical Sciences, Iran);
Hannelore K Neuhauser (Robert Koch Institute,
Germany; German Center for Cardiovascular
Research, Germany); Maroje Soric (University of
Zagreb, Croatia); Gregor Starc (University of
Ljubljana, Slovenia); Johan Sundstro¨m (Uppsala
University, Sweden); Mark Woodward (University of
New South Wales, Australia; University of Oxford,
UK); Majid Ezzati (Imperial College London, UK)
Country and Regional Data
(* equal contribution; listed alphabetically)
Leandra Abarca-Go´mez (Caja Costarricense de
Seguro Social, Costa Rica)*; Ziad A Abdeen (Al-Quds
University, Palestine)*; Niveen M Abu-Rmeileh
(Birzeit University, Palestine)*; Benjamin Acosta-
Cazares (Instituto Mexicano del Seguro Social,
Mexico)*; Robert J Adams (The University of
Adelaide, Australia)*; Wichai Aekplakorn (Mahidol
University, Thailand)*; Kaosar Afsana (BRAC,
Bangladesh)*; Carlos A Aguilar-Salinas (Instituto
Nacional de Ciencias Me´dicas y Nutricion, Mexico)*;
Charles Agyemang (University of Amsterdam, The
Netherlands)*; Noor Ani Ahmad (Ministry of Health
Malaysia, Malaysia)*; Alireza Ahmadvand (Non-
Communicable Diseases Research Center, Iran)*;
Wolfgang Ahrens (Leibniz Institute for Prevention
Research and Epidemiology - BIPS, Germany)*;
Kamel Ajlouni (National Center for Diabetes and
Endocrinology, Jordan)*; Nazgul Akhtaeva (Kazakh
National Medical University, Kazakhstan)*; Rajaa Al-
Raddadi (King Abdulaziz University, Saudi Arabia)*;
Mohamed M Ali (World Health Organization,
Switzerland)*; Osman Ali (Universiti Malaysia Sabah,
Malaysia)*; Ala’a Alkerwi (Luxembourg Institute of
Health, Luxembourg)*; Eman Aly (World Health
Organization Regional Office for the Eastern
Mediterranean, Egypt)*; Deepak N Amarapurkar
(Bombay Hospital and Medical Research Centre,
India)*; Philippe Amouyel (Lille University and
Hospital, France)*; Antoinette Amuzu (London
School of Hygiene & Tropical Medicine, UK)*; Lars
Bo Andersen (Western Norway University of Applied
Sciences, Norway)*; Sigmund A Anderssen
(Norwegian School of Sport Sciences, Norway)*; Lars
H A¨ngquist (Bispebjerg and Frederiksberg Hospitals,
Denmark)*; Ranjit Mohan Anjana (Madras Diabetes
Research Foundation, India)*; Daniel Ansong (Komfo
Anokye Teaching Hospital, Ghana)*; Hajer
Aounallah-Skhiri (National Institute of Public Health,
Tunisia)*; Joana Arau´jo (Universidade do Porto,
Portugal)*; Inger Ariansen (Norwegian Institute of
Public Health, Norway)*; Tahir Aris (Ministry of
Health Malaysia, Malaysia)*; Nimmathota Arlappa
(National Institute of Nutrition, India)*; Dominique
Arveiler (Strasbourg University and Hospital,
France)*; Krishna K Aryal (Nepal Health Research
Council, Nepal)*; Thor Aspelund (University of
Iceland, Iceland)*; Felix K Assah (University of
Yaounde´ 1, Cameroon)*; Maria Cecı´lia F Assunc¸~ao
(Federal University of Pelotas, Brazil)*; Ma´ria
Avdicova´ (Regional Authority of Public Health,
Banska Bystrica, Slovakia)*; Ana Azevedo (University
of Porto Medical School, Portugal)*; Fereidoun Azizi
(Shahid Beheshti University of Medical Sciences,
Iran)*; Bontha V Babu (Indian Council of Medical
Research, India)*; Suhad Bahijri (King Abdulaziz
University, Saudi Arabia)*; Nagalla Balakrishna
(National Institute of Nutrition, India)*; Mohamed
Bamoshmoosh (University of Science and Technology,
Yemen)*; Maciej Banach (Medical University of Lodz,
Poland)*; Piotr Bandosz (Medical University of
Gdansk, Poland)*; Jose´ R Banegas (Universidad
Auto´noma de Madrid, Spain)*; Carlo M Barbagallo
(University of Palermo, Italy)*; Alberto Barcelo´ (Pan
American Health Organization, USA)*; Amina Barkat
(Universite´ Mohammed V de Rabat, Morocco)*;
Aluisio JD Barros (Federal University of Pelotas,
Brazil)*; Mauro V Barros (University of Pernambuco,
Brazil)*; Iqbal Bata (Dalhousie University, Canada)*;
Anwar M Batieha (Jordan University of Science and
Technology, Jordan)*; Assembekov Batyrbek (Kazakh
National Medical University, Kazakhstan)*; Louise A
Baur (University of Sydney, Australia)*; Robert
Beaglehole (University of Auckland, New Zealand)*;
Habiba Ben Romdhane (University Tunis El Manar,
883a International Journal of Epidemiology, 2018, Vol. 47, No. 3
Tunisia)*; Mikhail Benet (CAFAM University
Foundation, Colombia)*; Lowell S Benson (University
of Utah School of Medicine, USA)*; Antonio Bernabe-
Ortiz (Universidad Peruana Cayetano Heredia, Peru)*;
Gailute Bernotiene (Lithuanian University of Health
Sciences, Lithuania)*; Heloisa Bettiol (University of
S~ao Paulo, Brazil)*; Aroor Bhagyalaxmi (BJ Medical
College, India)*; Sumit Bharadwaj (Chirayu Medical
College, India)*; Santosh K Bhargava (SL Jain
Hospital, India)*; Yufang Bi (Shanghai Jiao-Tong
University School of Medicine, China)*; Mukharram
Bikbov (Ufa Eye Research Institute, Russia)*;
Bihungum Bista (Nepal Health Research Council,
Nepal)*; Peter Bjerregaard (University of Southern
Denmark, Denmark; University of Greenland,
Greenland)*; Espen Bjertness (University of Oslo,
Norway)*; Marius B Bjertness (University of Oslo,
Norway)*; Cecilia Bjo¨rkelund (University of
Gothenburg, Sweden)*; Anneke Blokstra (National
Institute for Public Health and the Environment, The
Netherlands)*; Simona Bo (University of Turin, Italy)*;
Martin Bobak (University College London, UK)*;
Heiner Boeing (German Institute of Human Nutrition,
Germany)*; Jose G Boggia (Universidad de la
Repu´blica, Uruguay)*; Carlos P Boissonnet (CEMIC,
Argentina)*; Vanina Bongard (Toulouse University
School of Medicine, France)*; Rossana Borchini
(University Hospital of Varese, Italy)*; Pascal Bovet
(Ministry of Health, Seychelles; University of
Lausanne, Switzerland)*; Lutgart Braeckman (Ghent
University, Belgium)*; Imperia Brajkovich (Universidad
Central de Venezuela, Venezuela)*; Francesco Branca
(World Health Organization, Switzerland)*; Juergen
Breckenkamp (Bielefeld University, Germany)*;
Hermann Brenner (German Cancer Research Center,
Germany)*; Lizzy M Brewster (University of
Amsterdam, The Netherlands)*; Graziella Bruno
(University of Turin, Italy)*; H.B(as) Bueno-de-
Mesquita (National Institute for Public Health and the
Environment, The Netherlands)*; Anna Bugge
(University of Southern Denmark, Denmark)*; Con
Burns (Cork Institute of Technology, Ireland)*;
Michael Bursztyn (Hadassah-Hebrew University
Medical Center, Israel)*; Antonio Cabrera de Leo´n
(Universidad de La Laguna, Spain)*; Joseph
Cacciottolo (University of Malta, Malta)*; Hui Cai
(Vanderbilt University, USA)*; Christine Cameron
(Canadian Fitness and Lifestyle Research Institute,
Canada)*; Gu¨nay Can (Istanbul University, Turkey)*;
Ana Paula C Caˆndido (Universidade Federal de Juiz de
Fora, Brazil)*; Vincenzo Capuano (Cardiologia di
Mercato S. Severino, Italy)*; Viviane C Cardoso
(University of S~ao Paulo, Brazil)*; Axel C Carlsson
(Karolinska Institutet, Sweden)*; Maria J Carvalho
(University of Porto, Portugal)*; Felipe F Casanueva
(Santiago de Compostela University, Spain)*; Juan-
Pablo Casas (University College London, UK)*;
Carmelo A Caserta (Associazione Calabrese di
Epatologia, Italy)*; Snehalatha Chamukuttan (India
Diabetes Research Foundation, India)*; Angelique W
Chan (Duke-NUS Medical School, Singapore)*;
Queenie Chan (Imperial College London, UK)*;
Himanshu K Chaturvedi (National Institute of Medical
Statistics, India)*; Nishi Chaturvedi (University College
London, UK)*; Chien-Jen Chen (Academia Sinica,
Taiwan)*; Fangfang Chen (Capital Institute of
Pediatrics, China)*; Huashuai Chen (Duke University,
USA)*; Shuohua Chen (Kailuan General Hospital,
China)*; Zhengming Chen (University of Oxford,
UK)*; Ching-Yu Cheng (Duke-NUS Medical School,
Singapore)*; Imane Cherkaoui Dekkaki (Universite´
Mohammed V de Rabat, Morocco)*; Angela Chetrit
(The Gertner Institute for Epidemiology and Health
Policy Research, Israel)*; Arnaud Chiolero (University
of Bern, Switzerland)*; Shu-Ti Chiou (Ministry of
Health and Welfare, Taiwan)*; Adela Chirita-Emandi
(Victor Babes University of Medicine and Pharmacy
Timisoara, Romania)*; Marı´a-Dolores Chirlaque
(Murcia Regional Health Council, Spain)*; Belong Cho
(Seoul National University College of Medicine,
Republic of Korea)*; Yumi Cho (Korea Centers for
Disease Control and Prevention, Republic of Korea)*;
Diego G Christofaro (Universidade Estadual Paulista,
Brazil)*; Jerzy Chudek (Medical University of Silesia,
Poland)*; Renata Cifkova (Charles University in
Prague, Czech Republic)*; Eliza Cinteza (Carol Davila
University of Medicine and Pharmacy, Romania)*;
Frank Claessens (Katholieke Universiteit Leuven,
Belgium)*; Els Clays (Ghent University, Belgium)*;
Hans Concin (Agency for Preventive and Social
Medicine, Austria)*; Cyrus Cooper (University of
Southampton, UK)*; Rachel Cooper (University
College London, UK)*; Tara C Coppinger (Cork
Institute of Technology, Ireland)*; Simona Costanzo
(IRCCS Istituto Neurologico Mediterraneo Neuromed,
Italy)*; Dominique Cottel (Institut Pasteur de Lille,
France)*; Chris Cowell (University of Sydney,
Australia)*; Cora L Craig (Canadian Fitness and
Lifestyle Research Institute, Canada)*; Ana B Crujeiras
(CIBEROBN, Spain)*; Juan J Cruz (Universidad
Auto´noma de Madrid, Spain)*; Graziella D’Arrigo
(National Council of Research, Italy)*; Eleonora d’Orsi
(Universidade Federal de Santa Catarina, Brazil)*; Jean
Dallongeville (Institut Pasteur de Lille, France)*;
Albertino Damasceno (Eduardo Mondlane University,
Mozambique)*; Goodarz Danaei (Harvard TH Chan
School of Public Health, USA)*; Rachel Dankner (The
Gertner Institute for Epidemiology and Health Policy
Research, Israel)*; Thomas M Dantoft (Bispebjerg and
Frederiksberg Hospital, Denmark)*; Luc Dauchet (Lille
University Hospital, France)*; Kairat Davletov
(Kazakh National Medical University, Kazakhstan)*;
Guy De Backer (Ghent University, Belgium)*; Dirk De
Bacquer (Ghent University, Belgium)*; Giovanni de
Gaetano (IRCCS Istituto Neurologico Mediterraneo
Neuromed, Italy)*; Stefaan De Henauw (Ghent
University, Belgium)*; Paula Duarte de Oliveira
(Federal University of Pelotas, Brazil)*; Delphine De
Smedt (Ghent University, Belgium)*; Mohan Deepa
(Madras Diabetes Research Foundation, India)*;
Abbas Dehghan (Erasmus Medical Center Rotterdam,
The Netherlands)*; He´le`ne Delisle (University of
International Journal of Epidemiology, 2018, Vol. 47, No. 3 883b
Montreal, Canada)*; Vale´rie Deschamps (French
Public Health Agency, France)*; Klodian Dhana
(Erasmus Medical Center Rotterdam, The
Netherlands)*; Augusto F Di Castelnuovo (IRCCS
Istituto Neurologico Mediterraneo Neuromed, Italy)*;
Juvenal Soares Dias-da-Costa (Universidade do Vale do
Rio dos Sinos, Brazil)*; Alejandro Diaz (National
Council of Scientific and Technical Research,
Argentina)*; Ty T Dickerson (University of Utah
School of Medicine, USA)*; Shirin Djalalinia (Tehran
University of Medical Sciences, Iran; Ministry of
Health and Medical Education, Iran)*; Ha TP Do
(National Institute of Nutrition, Vietnam)*; Annette J
Dobson (University of Queensland, Australia)*; Chiara
Donfrancesco (Istituto Superiore di Sanita`, Italy)*;
Silvana P Donoso (Universidad de Cuenca, Ecuador)*;
Angela Do¨ring (Helmholtz Zentrum Mu¨nchen,
Germany)*; Maria Dorobantu (Carol Davila
University of Medicine and Pharmacy, Romania)*;
Kouamelan Doua (Ministe`re de la Sante´ et de la Lutte
Contre le Sida, Coˆte d’Ivoire)*; Wojciech Drygas (The
Cardinal Wyszynski Institute of Cardiology, Poland)*;
Virginija Dulskiene (Lithuanian University of Health
Sciences, Lithuania)*; Aleksandar Dzakula (University
of Zagreb, Croatia)*; Vilnis Dzerve (University of
Latvia, Latvia)*; Elzbieta Dziankowska-Zaborszczyk
(Medical University of Lodz, Poland)*; Robert
Eggertsen (University of Gothenburg, Sweden)*; Ulf
Ekelund (Norwegian School of Sport Sciences,
Norway)*; Jalila El Ati (National Institute of Nutrition
and Food Technology, Tunisia)*; Paul Elliott (Imperial
College London, UK)*; Roberto Elosua (Institut
Hospital del Mar d’Investigacions Me`diques, Spain)*;
Rajiv T Erasmus (University of Stellenbosch, South
Africa)*; Cihangir Erem (Karadeniz Technical
University, Turkey)*; Louise Eriksen (University of
Southern Denmark, Denmark)*; Johan G Eriksson
(National Institute for Health and Welfare, Finland)*;
Jorge Escobedo-de la Pe~na (Instituto Mexicano del
Seguro Social, Mexico)*; Alun Evans (Queen’s
University of Belfast, UK)*; David Faeh (University of
Zurich, Switzerland)*; Caroline H Fall (University of
Southampton, UK)*; Farshad Farzadfar (Tehran
University of Medical Sciences, Iran)*; Francisco J
Felix-Redondo (Centro de Salud Villanueva Norte,
Spain)*; Trevor S Ferguson (The University of the West
Indies, Jamaica)*; Romulo A Fernandes (Universidade
Estadual Paulista, Brazil)*; Daniel Ferna´ndez-Berge´s
(Hospital Don Benito-Villanueva de la Serena, Spain)*;
Daniel Ferrante (Ministry of Health, Argentina)*;
Marika Ferrari (Council for Agricultural Research and
Economics, Italy)*; Catterina Ferreccio (Pontificia
Universidad Cato´lica de Chile, Chile)*; Jean Ferrieres
(Toulouse University School of Medicine, France)*;
Joseph D Finn (University of Manchester, UK)*; Krista
Fischer (University of Tartu, Estonia)*; Bernhard Fo¨ger
(Agency for Preventive and Social Medicine, Austria)*;
Leng Huat Foo (Universiti Sains Malaysia, Malaysia)*;
Ann-Sofie Forslund (Umea˚ University, Sweden)*;
Maria Forsner (Dalarna University, Sweden)*; Heba M
Fouad (World Health Organization Regional Office for
the Eastern Mediterranean, Egypt)*; Damian K Francis
(The University of the West Indies, Jamaica)*; Maria
do Carmo Franco (Federal University of S~ao Paulo,
Brazil)*; Oscar H Franco (Erasmus Medical Center
Rotterdam, The Netherlands)*; Guillermo Frontera
(Hospital Universitario Son Espases, Spain)*; Flavio D
Fuchs (Hospital de Clinicas de Porto Alegre, Brazil)*;
Sandra C Fuchs (Universidade Federal do Rio Grande
do Sul, Brazil)*; Yuki Fujita (Kindai University,
Japan)*; Takuro Furusawa (Kyoto University, Japan)*;
Zbigniew Gaciong (Medical University of Warsaw,
Poland)*; Fabio Galvano (University of Catania,
Italy)*; Manoli Garcia-de-la-Hera (CIBER en
Epidemiologı´a y Salud Pu´blica, Spain)*; Dickman
Gareta (University of KwaZulu-Natal, South Africa)*;
Sarah P Garnett (University of Sydney, Australia)*;
Jean-Michel Gaspoz (Geneva University Hospitals,
Switzerland)*; Magda Gasull (CIBER en
Epidemiologı´a y Salud Pu´blica, Spain)*; Louise Gates
(Australian Bureau of Statistics, Australia)*; Johanna
M Geleijnse (Wageningen University, The
Netherlands)*; Anoosheh Ghasemian (Non-
Communicable Diseases Research Center, Iran)*; Anup
Ghimire (B P Koirala Institute of Health Sciences,
Nepal)*; Simona Giampaoli (Istituto Superiore di
Sanita`, Italy)*; Francesco Gianfagna (University of
Insubria, Italy; IRCCS Istituto Neurologico
Mediterraneo Neuromed, Italy)*; Tiffany K Gill (The
University of Adelaide, Australia)*; Jonathan
Giovannelli (Lille University Hospital, France)*;
Rebecca A Goldsmith (Ministry of Health, Israel)*;
Helen Gonc¸alves (Federal University of Pelotas,
Brazil)*; Marcela Gonzalez-Gross (Universidad
Polite´cnica de Madrid, Spain)*; Juan P Gonza´lez-Rivas
(The Andes Clinic of Cardio-Metabolic Studies,
Venezuela)*; Mariano Bonet Gorbea (National
Institute of Hygiene, Epidemiology and Microbiology,
Cuba)*; Frederic Gottrand (Universite´ de Lille 2,
France)*; Sidsel Graff-Iversen (Norwegian Institute of
Public Health, Norway)*; Dusan Grafnetter (Institute
for Clinical and Experimental Medicine, Czech
Republic)*; Aneta Grajda (Children’s Memorial Health
Institute, Poland)*; Maria G Grammatikopoulou
(Alexander Technological Educational Institute,
Greece)*; Ronald D Gregor (Dalhousie University,
Canada)*; Tomasz Grodzicki (Jagiellonian University
Medical College, Poland)*; Anders Grøntved
(University of Southern Denmark, Denmark)*;
Giuseppe Grosso (Azienda Ospedaliera Universitaria
Policlinico Vittorio Emanuele, Italy)*; Gabriella
Gruden (University of Turin, Italy)*; Vera Grujic
(University of Novi Sad, Serbia)*; Dongfeng Gu
(National Center of Cardiovascular Diseases, China)*;
Ong Peng Guan (Singapore Eye Research Institute,
Singapore)*; Elias F Gudmundsson (Icelandic Heart
Association, Iceland)*; Vilmundur Gudnason
(University of Iceland, Iceland)*; Ramiro Guerrero
(Universidad Icesi, Colombia)*; Idris Guessous
(Geneva University Hospitals, Switzerland)*; Andre L
Guimaraes (State University of Montes Claros,
Brazil)*; Martin C Gulliford (King’s College London,
883c International Journal of Epidemiology, 2018, Vol. 47, No. 3
UK)*; Johanna Gunnlaugsdottir (Icelandic Heart
Association, Iceland)*; Marc Gunter (International
Agency for Research on Cancer, France)*; Prakash C
Gupta (Healis-Sekhsaria Institute for Public Health,
India)*; Rajeev Gupta (Eternal Heart Care Centre &
Research Institute, India)*; Oye Gureje (University of
Ibadan, Nigeria)*; Beata Gurzkowska (Children’s
Memorial Health Institute, Poland)*; Laura Gutierrez
(Institute for Clinical Effectiveness and Health Policy,
Argentina)*; Felix Gutzwiller (University of Zurich,
Switzerland)*; Farzad Hadaegh (Shahid Beheshti
University of Medical Sciences, Iran)*; Jytte Halkjær
(Danish Cancer Society Research Centre, Denmark)*;
Ian R Hambleton (The University of the West Indies,
Barbados)*; Rebecca Hardy (University College
London, UK)*; Rachakulla Hari Kumar (National
Institute of Nutrition, India)*; Jun Hata (Kyushu
University, Japan)*; Alison J Hayes (University of
Sydney, Australia)*; Jiang He (Tulane University,
USA)*; Yuna He (Chinese Center for Disease Control
and Prevention, China)*; Marleen Elisabeth Hendriks
(Academic Medical Center of University of
Amsterdam, The Netherlands)*; Ana Henriques
(Universidade do Porto, Portugal)*; Leticia Hernandez
Cadena (National Institute of Public Health, Mexico)*;
Sauli Herrala (Oulu University Hospital, Finland)*;
Ramin Heshmat (Chronic Diseases Research Center,
Iran)*; Ilpo Tapani Hihtaniemi (Imperial College
London, UK)*; Sai Yin Ho (University of Hong Kong,
China)*; Suzanne C Ho (The Chinese University of
Hong Kong, China)*; Michael Hobbs (University of
Western Australia, Australia)*; Albert Hofman
(Erasmus Medical Center Rotterdam, The
Netherlands)*; Gonul Horasan Dinc (Celal Bayar
University, Turkey)*; Andrea RVR Horimoto (Heart
Institute, Brazil)*; Claudia M Hormiga (Fundacio´n
Oftalmolo´gica de Santander, Colombia)*; Bernardo L
Horta (Federal University of Pelotas, Brazil)*; Leila
Houti (University of Oran 1, Algeria)*; Christina
Howitt (The University of the West Indies, Barbados)*;
Thein Thein Htay (Independent Public Health
Specialist, Myanmar)*; Aung Soe Htet (Ministry of
Health, Myanmar)*; Maung Maung Than Htike
(Ministry of Health, Myanmar)*; Yonghua Hu (Peking
University, China)*; Jose´ Marı´a Huerta (CIBER en
Epidemiologı´a y Salud Pu´blica, Spain)*; Martijn
Huisman (VU University Medical Center and VU
University, The Netherlands)*; Abdullatif S Husseini
(Birzeit University, Palestine)*; Inge Huybrechts
(International Agency for Research on Cancer,
France)*; Nahla Hwalla (American University of
Beirut, Lebanon)*; Licia Iacoviello (IRCCS Istituto
Neurologico Mediterraneo Neuromed, Italy; University
of Insubria, Italy)*; Anna G Iannone (Cardiologia di
Mercato S. Severino, Italy)*; Mohsen M Ibrahim
(Cairo University, Egypt)*; Norazizah Ibrahim Wong
(Ministry of Health Malaysia, Malaysia)*; Nayu Ikeda
(National Institute of Health and Nutrition, Japan)*;
M Arfan Ikram (Erasmus Medical Center Rotterdam,
The Netherlands)*; Vilma E Irazola (Institute for
Clinical Effectiveness and Health Policy, Argentina)*;
Muhammad Islam (Aga Khan University, Pakistan)*;
Aziz al-Safi Ismail (Universiti Sains Malaysia,
Malaysia)*; Vanja Ivkovic (UHC Zagreb, Croatia)*;
Masanori Iwasaki (Niigata University, Japan)*; Rod T
Jackson (University of Auckland, New Zealand)*;
Jeremy M Jacobs (Hadassah University Medical
Center, Israel)*; Hashem Jaddou (Jordan University of
Science and Technology, Jordan)*; Tazeen Jafar (Duke-
NUS Medical School, Singapore)*; Konrad Jamrozik
(The University of Adelaide, Australia; deceased)*;
Imre Janszky (Norwegian University of Science and
Technology, Norway)*; Grazyna Jasienska
(Jagiellonian University Medical College, Poland)*;
Ana Jelakovic (UHC Zagreb, Croatia)*; Bojan
Jelakovic (University of Zagreb School of Medicine,
Croatia)*; Garry Jennings (Heart Foundation,
Australia)*; Seung-lyeal Jeong (National Health
Insurance Service, Republic of Korea)*; Chao Qiang
Jiang (Guangzhou 12th Hospital, China)*; Michel
Joffres (Simon Fraser University, Canada)*; Mattias
Johansson (International Agency for Research on
Cancer, France)*; Jari J Jokelainen (Oulu University
Hospital, Finland)*; Jost B Jonas (Ruprecht-Karls-
University of Heidelberg, Germany)*; Torben
Jørgensen (Research Centre for Prevention and Health,
Denmark)*; Pradeep Joshi (World Health
Organization Country Office, India)*; Jacek Jo´zwiak
(Czestochowa University of Technology, Poland)*;
Anne Juolevi (National Institute for Health and
Welfare, Finland)*; Gregor Jurak (University of
Ljubljana, Slovenia)*; Vesna Juresa (University of
Zagreb, Croatia)*; Rudolf Kaaks (German Cancer
Research Center, Germany)*; Anthony Kafatos
(University of Crete, Greece)*; Eero O Kajantie
(National Institute for Health and Welfare, Finland)*;
Ofra Kalter-Leibovici (The Gertner Institute for
Epidemiology and Health Policy Research, Israel)*;
Nor Azmi Kamaruddin (Universiti Kebangsaan
Malaysia, Malaysia)*; Khem B Karki (Nepal Health
Research Council, Nepal)*; Amir Kasaeian (Tehran
University of Medical Sciences, Iran)*; Joanne Katz
(Johns Hopkins Bloomberg School of Public Health,
USA)*; Jussi Kauhanen (University of Eastern Finland,
Finland)*; Prabhdeep Kaur (National Institute of
Epidemiology, India)*; Maryam Kavousi (Erasmus
Medical Center Rotterdam, The Netherlands)*; Gyulli
Kazakbaeva (Ufa Eye Research Institute, Russia)*;
Ulrich Keil (University of Mu¨nster, Germany)*; Lital
Keinan Boker (Israel Center for Disease Control,
Israel)*; Sirkka Keina¨nen-Kiukaanniemi (Oulu
University Hospital, Finland)*; Roya Kelishadi
(Research Institute for Primordial Prevention of Non-
communicable Disease, Iran)*; Han CG Kemper (VU
University Medical Center, The Netherlands)*; Andre
P Kengne (South African Medical Research Council,
South Africa)*; Alina Kerimkulova (Kyrgyz State
Medical Academy, Kyrgyzstan)*; Mathilde Kersting
(Research Institute of Child Nutrition, Germany)*;
Timothy Key (University of Oxford, UK)*; Yousef
Saleh Khader (Jordan University of Science and
Technology, Jordan)*; Davood Khalili (Shahid
International Journal of Epidemiology, 2018, Vol. 47, No. 3 883d
Beheshti University of Medical Sciences, Iran)*; Young-
Ho Khang (Seoul National University, Republic of
Korea)*; Mohammad Khateeb (National Center for
Diabetes and Endocrinology, Jordan)*; Kay-Tee Khaw
(University of Cambridge, UK)*; Ursula Kiechl-
Kohlendorfer (Medical University of Innsbruck,
Austria)*; Stefan Kiechl (Medical University of
Innsbruck, Austria)*; Japhet Killewo (Muhimbili
University of Health and Allied Sciences, Tanzania)*;
Jeongseon Kim (National Cancer Center, Republic of
Korea)*; Yeon-Yong Kim (National Health Insurance
Service, Republic of Korea)*; Jurate Klumbiene
(Lithuanian University of Health Sciences, Lithuania)*;
Michael Knoflach (Medical University of Innsbruck,
Austria)*; Elin Kolle (Norwegian School of Sport
Sciences, Norway)*; Patrick Kolsteren (Institute of
Tropical Medicine, Belgium)*; Paul Korrovits (Tartu
University Clinics, Estonia)*; Seppo Koskinen
(National Institute for Health and Welfare, Finland)*;
Katsuyasu Kouda (Kindai University, Japan)*; Sudhir
Kowlessur (Ministry of Health and Quality of Life,
Mauritius)*; Slawomir Koziel (Polish Academy of
Sciences Anthropology Unit in Wroclaw, Poland)*;
Susi Kriemler (University of Zu¨rich, Switzerland)*;
Peter Lund Kristensen (University of Southern
Denmark, Denmark)*; Steinar Krokstad (Norwegian
University of Science and Technology, Norway)*;
Daan Kromhout (University of Groningen, The
Netherlands)*; Herculina S Kruger (North-West
University, South Africa)*; Ruzena Kubinova (National
Institute of Public Health, Czech Republic)*; Renata
Kuciene (Lithuanian University of Health Sciences,
Lithuania)*; Diana Kuh (University College London,
UK)*; Urho M Kujala (University of Jyva¨skyla¨,
Finland)*; Zbigniew Kulaga (Children’s Memorial
Health Institute, Poland)*; R Krishna Kumar (Amrita
Institute of Medical Sciences, India)*; Pawel Kurjata
(The Cardinal Wyszynski Institute of Cardiology,
Poland)*; Yadlapalli S Kusuma (All India Institute of
Medical Sciences, India)*; Kari Kuulasmaa (National
Institute for Health and Welfare, Finland)*; Catherine
Kyobutungi (African Population and Health Research
Center, Kenya)*; Tiina Laatikainen (National Institute
for Health and Welfare, Finland)*; Carl Lachat (Ghent
University, Belgium)*; Tai Hing Lam (University of
Hong Kong, China)*; Orlando Landrove (Ministerio
de Salud Pu´blica, Cuba)*; Vera Lanska (Institute for
Clinical and Experimental Medicine, Czech
Republic)*; Georg Lappas (Sahlgrenska Academy,
Sweden)*; Bagher Larijani (Endocrinology and
Metabolism Research Center, Iran)*; Lars E Laugsand
(Norwegian University of Science and Technology,
Norway)*; Avula Laxmaiah (National Institute of
Nutrition, India)*; Khanh Le Nguyen Bao (National
Institute of Nutrition, Vietnam)*; Tuyen D Le
(National Institute of Nutrition, Vietnam)*; Catherine
Leclercq (Food and Agriculture Organization of the
United Nations, Italy)*; Jeannette Lee (National
University of Singapore, Singapore)*; Jeonghee Lee
(National Cancer Center, Republic of Korea)*; Terho
Lehtima¨ki (Tampere University Hospital, Finland)*;
Luz M Leo´n-Mu~noz (Universidad Auto´noma de
Madrid, Spain)*; Naomi S Levitt (University of Cape
Town, South Africa)*; Yanping Li (Harvard TH Chan
School of Public Health, USA)*; Christa L Lilly (West
Virginia University, USA)*; Wei-Yen Lim (National
University of Singapore, Singapore)*; M Fernanda
Lima-Costa (Oswaldo Cruz Foundation Rene Rachou
Research Institute, Brazil)*; Hsien-Ho Lin (National
Taiwan University, Taiwan)*; Xu Lin (University of
Chinese Academy of Sciences, China)*; Lars Lind
(Uppsala University, Sweden)*; Allan Linneberg
(Bispebjerg and Frederiksberg Hospital, Denmark)*;
Lauren Lissner (University of Gothenburg, Sweden)*;
Mieczyslaw Litwin (Children’s Memorial Health
Institute, Poland)*; Jing Liu (Capital Medical
University Beijing An Zhen Hospital, China)*; Roberto
Lorbeer (University Medicine Greifswald, Germany)*;
Paulo A Lotufo (University of S~ao Paulo, Brazil)*; Jose´
Eugenio Lozano (Consejerı´a de Sanidad Junta de
Castilla y Leo´n, Spain)*; Dalia Luksiene (Lithuanian
University of Health Sciences, Lithuania)*; Annamari
Lundqvist (National Institute for Health and Welfare,
Finland)*; Nuno Lunet (Universidade do Porto,
Portugal)*; Per Lytsy (University of Uppsala,
Sweden)*; Guansheng Ma (Peking University, China)*;
Jun Ma (Peking University, China)*; George LL
Machado-Coelho (Universidade Federal de Ouro Preto,
Brazil)*; Suka Machi (The Jikei University School of
Medicine, Japan)*; Stefania Maggi (National Research
Council, Italy)*; Dianna J Magliano (Baker Heart and
Diabetes Institute, Australia)*; Emmanuella Magriplis
(Agricultural University of Athens, Greece)*; Marjeta
Majer (University of Zagreb, Croatia)*; Marcia
Makdisse (Hospital Israelita Albert Einstein, Brazil)*;
Reza Malekzadeh (Shiraz University of Medical
Sciences, Iran)*; Rahul Malhotra (Duke-NUS Medical
School, Singapore)*; Kodavanti Mallikharjuna Rao
(National Institute of Nutrition, India)*; Sofia
Malyutina (Institute of Internal and Preventive
Medicine, Russia)*; Yannis Manios (Harokopio
University, Greece)*; Jim I Mann (University of Otago,
New Zealand)*; Enzo Manzato (University of Padova,
Italy)*; Paula Margozzini (Pontificia Universidad
Cato´lica de Chile, Chile)*; Pedro Marques-Vidal
(Lausanne University Hospital, Switzerland)*; Larissa
Pruner Marques (Universidade Federal de Santa
Catarina, Brazil)*; Jaume Marrugat (CIBERCV,
Spain)*; Reynaldo Martorell (Emory University,
USA)*; Ellisiv B Mathiesen (UiT The Arctic University
of Norway, Norway)*; Alicia Matijasevich (University
of S~ao Paulo, Brazil)*; Tandi E Matsha (Cape
Peninsula University of Technology, South Africa)*;
Jean Claude N Mbanya (University of Yaounde´ 1,
Cameroon)*; Anselmo J Mc Donald Posso (Gorgas
Memorial Institute of Health Studies, Panama)*; Shelly
R McFarlane (The University of the West Indies,
Jamaica)*; Stephen T McGarvey (Brown University,
USA)*; Stela McLachlan (University of Edinburgh,
UK)*; Rachael M McLean (University of Otago, New
Zealand)*; Scott B McLean (Statistics Canada,
Canada)*; Breige A McNulty (University College
883e International Journal of Epidemiology, 2018, Vol. 47, No. 3
Dublin, Ireland)*; Sounnia Mediene-Benchekor
(University of Oran 1, Algeria)*; Jurate Medzioniene
(Lithuanian University of Health Sciences, Lithuania)*;
Aline Meirhaeghe (Institut National de la Sante´ et de la
Recherche Me´dicale, France)*; Christa Meisinger
(Helmholtz Zentrum Mu¨nchen, Germany)*; Ana
Maria B Menezes (Federal University of Pelotas,
Brazil)*; Geetha R Menon (Indian Council of Medical
Research, India)*; Indrapal I Meshram (National
Institute of Nutrition, India)*; Andres Metspalu
(University of Tartu, Estonia)*; Haakon E Meyer
(University of Oslo, Norway)*; Jie Mi (Capital Institute
of Pediatrics, China)*; Kairit Mikkel (University of
Tartu, Estonia)*; Jody C Miller (University of Otago,
New Zealand)*; Cla´udia S Minderico (Luso´fona
University, Portugal)*; Juan Francisco Miquel
(Pontificia Universidad Cato´lica de Chile, Chile)*; J
Jaime Miranda (Universidad Peruana Cayetano
Heredia, Peru)*; Erkin Mirrakhimov (Kyrgyz State
Medical Academy, Kyrgyzstan)*; Marjeta Misigoj-
Durakovic (University of Zagreb, Croatia)*; Pietro A
Modesti (Universita’ degli Studi di Firenze, Italy)*;
Mostafa K Mohamed (Ain Shams University, Egypt)*;
Kazem Mohammad (Tehran University of Medical
Sciences, Iran)*; Noushin Mohammadifard
(Hypertension Research Center, Iran)*; Viswanathan
Mohan (Madras Diabetes Research Foundation,
India)*; Salim Mohanna (Universidad Peruana
Cayetano Heredia, Peru)*; Muhammad Fadhli Mohd
Yusoff (Ministry of Health Malaysia, Malaysia)*; Line
T Møllehave (Bispebjerg and Frederiksberg Hospital,
Denmark)*; Niels C Møller (University of Southern
Denmark, Denmark)*; De´nes Molna´r (University of
Pe´cs, Hungary)*; Amirabbas Momenan (Shahid
Beheshti University of Medical Sciences, Iran)*;
Charles K Mondo (Mulago Hospital, Uganda)*;
Kotsedi Daniel K Monyeki (University of Limpopo,
South Africa)*; Jin Soo Moon (Seoul National
University Children’s Hospital, Republic of Korea)*;
Leila B Moreira (Universidade Federal do Rio Grande
do Sul, Brazil)*; Alain Morejon (University Medical
Science, Cuba)*; Luis A Moreno (Universidad de
Zaragoza, Spain)*; Karen Morgan (RCSI Dublin,
Ireland)*; George Moschonis (La Trobe University,
Australia)*; Malgorzata Mossakowska (International
Institute of Molecular and Cell Biology, Poland)*; Aya
Mostafa (Ain Shams University, Egypt)*; Jorge Mota
(University of Porto, Portugal)*; Mohammad Esmaeel
Motlagh (Ahvaz Jundishapur University of Medical
Sciences, Iran)*; Jorge Motta (Gorgas Memorial
Institute of Public Health, Panama)*; Kelias P
Msyamboza (World Health Organization Country
Office, Malawi)*; Thet Thet Mu (Department of Public
Health, Myanmar)*; Maria L Muiesan (University of
Brescia, Italy)*; Martina Mu¨ller-Nurasyid (Helmholtz
Zentrum Mu¨nchen, Germany)*; Neil Murphy
(International Agency for Research on Cancer,
France)*; Jaakko Mursu (University of Eastern Finland,
Finland)*; Vera Musil (University of Zagreb,
Croatia)*; Iraj Nabipour (Bushehr University of
Medical Sciences, Iran)*; Gabriele Nagel (Ulm
University, Germany)*; Balkish M Naidu (Ministry of
Health Malaysia, Malaysia)*; Harunobu Nakamura
(Kobe University, Japan)*; Jana Na´mesna´ (Regional
Authority of Public Health, Banska Bystrica,
Slovakia)*; Ei Ei K Nang (National University of
Singapore, Singapore)*; Vinay B Nangia (Suraj Eye
Institute, India)*; Sameer Narake (Healis-Sekhsaria
Institute for Public Health, India)*; Matthias Nauck
(University Medicine of Greifswald, Germany)*; Eva
Maria Navarrete-Mu~noz (CIBER en Epidemiologı´a y
Salud Pu´blica, Spain)*; Ndeye Coumba Ndiaye
(INSERM, France)*; William A Neal (West Virginia
University, USA)*; Ilona Nenko (Jagiellonian
University Medical College, Poland)*; Martin Neovius
(Karolinska Institutet, Sweden)*; Flavio Nervi
(Pontificia Universidad Cato´lica de Chile, Chile)*;
Hannelore K Neuhauser (Robert Koch Institute,
Germany; German Center for Cardiovascular
Research, Germany)*; Chung T Nguyen (National
Institute of Hygiene and Epidemiology, Vietnam)*;
Nguyen D Nguyen (The University of Pharmacy and
Medicine of Ho Chi Minh City, Vietnam)*; Quang
Ngoc Nguyen (Hanoi Medical University, Vietnam)*;
Quang V Nguyen (National Hospital of
Endocrinology, Vietnam)*; Ramfis E Nieto-Martı´nez
(Miami Veterans Affairs Healthcare System, USA)*;
Teemu J Niiranen (University of Turku Tyks, Finland;
National Institute for Health and Welfare, Finland)*;
Guang Ning (Shanghai Jiao-Tong University School of
Medicine, China)*; Toshiharu Ninomiya (Kyushu
University, Japan)*; Sania Nishtar (Heartfile,
Pakistan)*; Marianna Noale (National Research
Council, Italy)*; Oscar A Noboa (Universidad de la
Repu´blica, Uruguay)*; Ahmad Ali Noorbala (Tehran
University of Medical Sciences, Iran)*; Teresa Norat
(Imperial College London, UK)*; Davide Noto
(University of Palermo, Italy)*; Mohannad Al Nsour
(Eastern Mediterranean Public Health Network,
Jordan)*; Dermot O’Reilly (Queen’s University of
Belfast, UK)*; Eiji Oda (Tachikawa General Hospital,
Japan)*; Glenn Oehlers (Academic Hospital of
Paramaribo, Suriname)*; Kyungwon Oh (Korea
Centers for Disease Control and Prevention, Republic
of Korea)*; Kumiko Ohara (Kobe University, Japan)*;
Maria Teresa A Olinto (Universidade do Vale do Rio
dos Sinos, Brazil)*; Isabel O Oliveira (Federal
University of Pelotas, Brazil)*; Mohd Azahadi Omar
(Ministry of Health Malaysia, Malaysia)*; Altan Onat
(Istanbul University, Turkey)*; Sok King Ong
(Ministry of Health, Brunei)*; Lariane M Ono
(Universidade Federal de Santa Catarina, Brazil)*;
Pedro Ordunez (Pan American Health Organization,
USA)*; Rui Ornelas (University of Madeira,
Portugal)*; Clive Osmond (MRC Lifecourse
Epidemiology Unit, UK)*; Sergej M Ostojic (University
of Novi Sad, Serbia)*; Afshin Ostovar (Bushehr
University of Medical Sciences, Iran)*; Johanna A
Otero (Fundacio´n Oftalmolo´gica de Santander,
Colombia)*; Kim Overvad (Aarhus University,
Denmark)*; Ellis Owusu-Dabo (Kwame Nkrumah
University of Science and Technology, Ghana)*; Fred
International Journal of Epidemiology, 2018, Vol. 47, No. 3 883f
Michel Paccaud (nstitute for Social and Preventive
Medicine, Switzerland)*; Cristina Padez (University of
Coimbra, Portugal)*; Elena Pahomova (University of
Latvia, Latvia)*; Andrzej Pajak (Jagiellonian University
Medical College, Poland)*; Domenico Palli (Cancer
Prevention and Research Institute, Italy)*; Luigi
Palmieri (Istituto Superiore di Sanita`, Italy)*; Wen-
Harn Pan (Academia Sinica, Taiwan)*; Songhomitra
Panda-Jonas (Ruprecht-Karls-University of Heidelberg,
Germany)*; Francesco Panza (IRCCS Casa Sollievo
della Sofferenza, Italy)*; Dimitrios Papandreou (Zayed
University, UAE)*; Soon-Woo Park (Catholic
University of Daegu, Republic of Korea)*; Winsome R
Parnell (University of Otago, New Zealand)*;
Mahboubeh Parsaeian (Tehran University of Medical
Sciences, Iran)*; Nikhil D Patel (Jivandeep Hospital,
India)*; Ivan Pecin (University of Zagreb School of
Medicine, Croatia; University Hospital Centre Zagreb,
Croatia)*; Mangesh S Pednekar (Healis-Sekhsaria
Institute for Public Health, India)*; Nasheeta Peer
(South African Medical Research Council, South
Africa)*; Petra H Peeters (University Medical Center
Utrecht, The Netherlands)*; Sergio Viana Peixoto
(Oswaldo Cruz Foundation Rene Rachou Research
Institute, Brazil)*; Markku Peltonen (National Institute
for Health and Welfare, Finland)*; Alexandre C
Pereira (Heart Institute, Brazil)*; Annette Peters
(Helmholtz Zentrum Mu¨nchen, Germany)*; Astrid
Petersmann (University Medicine of Greifswald,
Germany)*; Janina Petkeviciene (Lithuanian University
of Health Sciences, Lithuania)*; Niloofar Peykari
(Ministry of Health and Medical Education, Iran)*;
Son Thai Pham (Vietnam National Heart Institute,
Vietnam)*; Iris Pigeot (Leibniz Institute for Prevention
Research and Epidemiology - BIPS, Germany)*; Hynek
Pikhart (University College London, UK)*; Aida Pilav
(University of Sarajevo, Bosnia and Herzegovina)*;
Lorenza Pilotto (Cardiovascular Prevention Centre
Udine, Italy)*; Freda Pitakaka (Ministry of Health and
Medical Services, Solomon Islands)*; Aleksandra
Piwonska (The Cardinal Wyszynski Institute of
Cardiology, Poland)*; Pedro Plans-Rubio´ (Public
Health Agency of Catalonia, Spain)*; Ozren Polasek
(University of Split, Croatia)*; Miquel Porta (Institut
Hospital del Mar d’Investigacions Me`diques, Spain)*;
Marileen LP Portegies (Erasmus Medical Center
Rotterdam, The Netherlands)*; Akram Pourshams
(Digestive Oncology Research Center, Iran)*; Hossein
Poustchi (Digestive Disease Research Institute, Iran)*;
Rajendra Pradeepa (Madras Diabetes Research
Foundation, India)*; Mathur Prashant (Indian Council
of Medical Research, India)*; Jacqueline F Price
(University of Edinburgh, UK)*; Jardena J Puder
(Lausanne University Hospital, Switzerland)*; Maria
Puiu (Victor Babes University of Medicine and
Pharmacy Timisoara, Romania)*; Margus Punab
(Tartu University Clinics, Estonia)*; Radwan F
Qasrawi (Al-Quds University, Palestine)*; Mostafa
Qorbani (Alborz University of Medical Sciences,
Iran)*; Tran Quoc Bao (Ministry of Health,
Vietnam)*; Ivana Radic (University of Novi Sad,
Serbia)*; Ricardas Radisauskas (Lithuanian University
of Health Sciences, Lithuania)*; Mahfuzar Rahman
(BRAC, Bangladesh)*; Olli Raitakari (University of
Turku, Finland)*; Manu Raj (Amrita Institute of
Medical Sciences, India)*; Sudha Ramachandra Rao
(National Institute of Epidemiology, India)*; Ambady
Ramachandran (India Diabetes Research Foundation,
India)*; Elisabete Ramos (University of Porto Medical
School, Portugal)*; Lekhraj Rampal (Universiti Putra
Malaysia, Malaysia)*; Sanjay Rampal (University of
Malaya, Malaysia)*; Daniel A Rangel Reina (Gorgas
Memorial Institute of Health Studies, Panama)*; Josep
Redon (University of Valencia, Spain)*; Paul Ferdinand
M Reganit (University of the Philippines, Philippines)*;
Robespierre Ribeiro (Minas Gerais State Secretariat for
Health, Brazil)*; Elio Riboli (Imperial College London,
UK)*; Fernando Rigo (Health Center San Agustı´n,
Spain)*; Tobias F Rinke de Wit (PharmAccess
Foundation, The Netherlands)*; Raphael M Ritti-Dias
(Universidade Nove de Julho, Brazil)*; Sian M
Robinson (University of Southampton, UK)*; Cynthia
Robitaille (Public Health Agency of Canada, Canada)*;
Fernando Rodrı´guez-Artalejo (Universidad Auto´noma
de Madrid, Spain)*; Marı´a del Cristo Rodriguez-Perez
(Canarian Health Service, Spain)*; Laura A Rodrı´guez-
Villamizar (Universidad Industrial de Santander,
Colombia)*; Rosalba Rojas-Martinez (Instituto
Nacional de Salud Pu´blica, Mexico)*; Dora
Romaguera (CIBEROBN, Spain)*; Kimmo Ronkainen
(University of Eastern Finland, Finland)*; Annika
Rosengren (University of Gothenburg, Sweden)*; Joel
GR Roy (Statistics Canada, Canada)*; Adolfo
Rubinstein (Institute for Clinical Effectiveness and
Health Policy, Argentina)*; Blanca Sandra Ruiz-
Betancourt (Instituto Mexicano del Seguro Social,
Mexico)*; Marcin Rutkowski (Medical University of
Gdansk, Poland)*; Charumathi Sabanayagam
(Singapore Eye Research Institute, Singapore)*;
Harshpal S Sachdev (Sitaram Bhartia Institute of
Science and Research, India)*; Olfa Saidi (University
Tunis El Manar, Tunisia)*; Sibel Sakarya (Marmara
University, Turkey)*; Benoit Salanave (French Public
Health Agency, France)*; Eduardo Salazar Martinez
(National Institute of Public Health, Mexico)*; Diego
Salmero´n (CIBER de Epidemiologı´a y Salud Pu´blica,
Spain)*; Veikko Salomaa (National Institute for Health
and Welfare, Finland)*; Jukka T Salonen (University of
Helsinki, Finland)*; Massimo Salvetti (University of
Brescia, Italy)*; Jose Sa´nchez-Abanto (National
Institute of Health, Peru)*; Susana Sans (Catalan
Department of Health, Spain)*; Diana A Santos
(Universidade de Lisboa, Portugal)*; Ina S Santos
(Federal University of Pelotas, Brazil)*; Renata Nunes
dos Santos (University of Sao Paulo Clinics Hospital,
Brazil)*; Rute Santos (University of Porto, Portugal)*;
Jouko L Saramies (South Karelia Social and Health
Care District, Finland)*; Luis B Sardinha (Universidade
de Lisboa, Portugal)*; Giselle Sarganas (Robert Koch
Institute, Germany)*; Nizal Sarrafzadegan (Isfahan
Cardiovascular Research Center, Iran)*; Kai-Uwe
Saum (German Cancer Research Center, Germany)*;
883g International Journal of Epidemiology, 2018, Vol. 47, No. 3
Savvas Savva (Research and Education Institute of
Child Health, Cyprus)*; Marcia Scazufca (University
of Sao Paulo Clinics Hospital, Brazil)*; Herman
Schargrodsky (Hospital Italiano de Buenos Aires,
Argentina)*; Sabine Schipf (University Medicine of
Greifswald, Germany)*; Carsten O Schmidt (University
Medicine of Greifswald, Germany)*; Ben Scho¨ttker
(German Cancer Research Center, Germany)*;
Constance Schultsz (Academic Medical Center of
University of Amsterdam, The Netherlands)*; Aletta E
Schutte (South African Medical Research Council,
South Africa; North-West University, South Africa)*;
Aye Aye Sein (Ministry of Health, Myanmar)*; Abhijit
Sen (Norwegian University of Science and Technology,
Norway)*; Idowu O Senbanjo (Lagos State University
College of Medicine, Nigeria)*; Sadaf G Sepanlou
(Tehran University of Medical Sciences, Iran)*; Sanjib
K Sharma (B P Koirala Institute of Health Sciences,
Nepal)*; Jonathan E Shaw (Baker Heart and Diabetes
Institute, Australia)*; Kenji Shibuya (The University of
Tokyo, Japan)*; Dong Wook Shin (Samsung Medical
Center, Republic of Korea)*; Youchan Shin (Singapore
Eye Research Institute, Singapore)*; Khairil Si-Ramlee
(Ministry of Health, Brunei)*; Rosalynn Siantar
(Singapore Eye Research Institute, Singapore)*; Abla
M Sibai (American University of Beirut, Lebanon)*;
Diego Augusto Santos Silva (Federal University of
Santa Catarina, Brazil)*; Mary Simon (India Diabetes
Research Foundation, India)*; Judith Simons (St
Vincent’s Hospital, Australia)*; Leon A Simons
(University of New South Wales, Australia)*; Michael
Sjo¨stro¨m (Karolinska Institutet, Sweden)*; Sine
Skovbjerg (Bispebjerg and Frederiksberg Hospital,
Denmark)*; Jolanta Slowikowska-Hilczer (Medical
University of Lodz, Poland)*; Przemyslaw Slusarczyk
(International Institute of Molecular and Cell Biology,
Poland)*; Liam Smeeth (London School of Hygiene &
Tropical Medicine, UK)*; Margaret C Smith
(University of Oxford, UK)*; Marieke B Snijder
(Academic Medical Center Amsterdam, The
Netherlands)*; Hung-Kwan So (University of Hong
Kong, China)*; Euge`ne Sobngwi (University of
Yaounde´ 1, Cameroon)*; Stefan So¨derberg (Umea˚
University, Sweden)*; Vincenzo Solfrizzi (University of
Bari, Italy)*; Emily Sonestedt (Lund University,
Sweden)*; Yi Song (Peking University, China)*;
Thorkild IA Sørensen (University of Copenhagen,
Denmark)*; Maroje Soric (University of Zagreb,
Croatia)*; Charles Sossa Je´rome (Institut Re´gional de
Sante´ Publique, Benin)*; Aicha Soumare (University of
Bordeaux, France)*; Jan A Staessen (University of
Leuven, Belgium)*; Gregor Starc (University of
Ljubljana, Slovenia)*; Maria G Stathopoulou
(INSERM, France)*; Bill Stavreski (Heart Foundation,
Australia)*; Jostein Steene-Johannessen (Norwegian
School of Sport Sciences, Norway)*; Peter Stehle (Bonn
University, Germany)*; Aryeh D Stein (Emory
University, USA)*; George S Stergiou (Sotiria Hospital,
Greece)*; Jochanan Stessman (Hadassah University
Medical Center, Israel)*; Jutta Stieber (Helmholtz
Zentrum Mu¨nchen, Germany; deceased)*; Doris Sto¨ckl
(Helmholtz Zentrum Mu¨nchen, Germany)*; Tanja
Stocks (Lund University, Sweden)*; Jakub
Stokwiszewski (National Institute of Public Health-
National Institute of Hygiene, Poland)*; Karien
Stronks (University of Amsterdam, The Netherlands)*;
Maria Wany Strufaldi (Federal University of S~ao Paulo,
Brazil)*; Chien-An Sun (Fu Jen Catholic University,
Taiwan)*; Johan Sundstro¨m (Uppsala University,
Sweden)*; Yn-Tz Sung (The Chinese University of
Hong Kong, China)*; Paibul Suriyawongpaisal
(Mahidol University, Thailand)*; Rody G Sy
(University of the Philippines, Philippines)*; E Shyong
Tai (National University of Singapore, Singapore)*;
Mari-Liis Tammesoo (University of Tartu, Estonia)*;
Abdonas Tamosiunas (Lithuanian University of Health
Sciences, Lithuania)*; Eng Joo Tan (University of
Sydney, Australia)*; Xun Tang (Peking University,
China)*; Frank Tanser (University of KwaZulu-Natal,
South Africa)*; Yong Tao (Peking University, China)*;
Mohammed Rasoul Tarawneh (Ministry of Health,
Jordan)*; Carolina B Tarqui-Mamani (National
Institute of Health, Peru)*; Oana-Florentina Tautu
(Carol Davila University of Medicine and Pharmacy,
Romania)*; Anne Taylor (The University of Adelaide,
Australia)*; Holger Theobald (Karolinska Institutet,
Sweden)*; Xenophon Theodoridis (Alexander
Technological Educational Institute, Greece)*;
Lutgarde Thijs (University of Leuven, Belgium)*;
Betina H Thuesen (Bispebjerg and Frederiksberg
Hospital, Denmark)*; Anne Tjonneland (Danish
Cancer Society Research Centre, Denmark)*; Hanna K
Tolonen (National Institute for Health and Welfare,
Finland)*; Janne S Tolstrup (University of Southern
Denmark, Denmark)*; Murat Topbas (Karadeniz
Technical University, Turkey)*; Roman Topo´r-Madry
(Jagiellonian University Medical College, Poland)*;
Marı´a Jose´ Tormo (Health Service of Murcia, Spain)*;
Maties Torrent (IB-SALUT Area de Salut de Menorca,
Spain)*; Pierre Traissac (Institut de Recherche pour le
De´veloppement, France)*; Dimitrios Trichopoulos
(Harvard TH Chan School of Public Health, USA;
deceased)*; Antonia Trichopoulou (Hellenic Health
Foundation, Greece)*; Oanh TH Trinh (The University
of Pharmacy and Medicine of Ho Chi Minh City,
Vietnam)*; Atul Trivedi (Government Medical College,
India)*; Lechaba Tshepo (Sefako Makgatho Health
Science University, South Africa)*; Marshall K
Tulloch-Reid (The University of the West Indies,
Jamaica)*; Fikru Tullu (Addis Ababa University,
Ethiopia)*; Tomi-Pekka Tuomainen (University of
Eastern Finland, Finland)*; Jaakko Tuomilehto
(Dasman Diabetes Institute, Kuwait)*; Maria L Turley
(Ministry of Health, New Zealand)*; Per Tynelius
(Karolinska Institutet, Sweden)*; Christophe Tzourio
(University of Bordeaux, France)*; Peter Ueda
(Harvard TH Chan School of Public Health, USA)*;
Eunice E Ugel (Universidad Centro-Occidental
Lisandro Alvarado, Venezuela)*; Hanno Ulmer
(Medical University of Innsbruck, Austria)*; Hannu
MT Uusitalo (University of Tampere Tays Eye Center,
Finland)*; Gonzalo Valdivia (Pontificia Universidad
International Journal of Epidemiology, 2018, Vol. 47, No. 3 883h
Cato´lica de Chile, Chile)*; Damaskini Valvi (Harvard
TH Chan School of Public Health, USA)*; Yvonne T
van der Schouw (Utrecht University, The
Netherlands)*; Koen Van Herck (Ghent University,
Belgium)*; Hoang Van Minh (Hanoi University of
Public Health, Vietnam)*; Lenie van Rossem
(University Medical Center Utrecht, The
Netherlands)*; Natasja M Van Schoor (Amsterdam
Public Health Research Institute, The Netherlands)*;
Irene GM van Valkengoed (Academic Medical Center
Amsterdam, The Netherlands)*; Dirk Vanderschueren
(Katholieke Universiteit Leuven, Belgium)*; Diego
Vanuzzo (Cardiovascular Prevention Centre Udine,
Italy)*; Lars Vatten (Norwegian University of Science
and Technology, Norway)*; Tomas Vega (Consejerı´a
de Sanidad Junta de Castilla y Leo´n, Spain)*; Gustavo
Velasquez-Melendez (Universidade Federal de Minas
Gerais, Brazil)*; Giovanni Veronesi (University of
Insubria, Italy)*; WM Monique Verschuren (National
Institute for Public Health and the Environment, The
Netherlands)*; Roosmarijn Verstraeten (Institute of
Tropical Medicine, Belgium)*; Cesar G Victora
(Federal University of Pelotas, Brazil)*; Lucie Viet
(National Institute for Public Health and the
Environment, The Netherlands)*; Eira Viikari-Juntura
(Finnish Institute of Occupational Health, Finland)*;
Paolo Vineis (Imperial College London, UK)*; Jesus
Vioque (Universidad Miguel Hernandez, Spain)*; Jyrki
K Virtanen (University of Eastern Finland, Finland)*;
Sophie Visvikis-Siest (INSERM, France)*; Bharathi
Viswanathan (Ministry of Health, Seychelles)*; Tiina
Vlasoff (North Karelian Center for Public Health,
Finland)*; Peter Vollenweider (Lausanne University
Hospital, Switzerland)*; Sari Voutilainen (University of
Eastern Finland, Finland)*; Alisha N Wade (University
of the Witwatersrand, South Africa)*; Aline Wagner
(University of Strasbourg, France)*; Janette Walton
(Cork Institute of Technology, Ireland)*; Wan
Mohamad Wan Bebakar (Universiti Sains Malaysia,
Malaysia)*; Wan Nazaimoon Wan Mohamud
(Institute for Medical Research, Malaysia)*; Rildo S
Wanderley Jr. (University of Pernambuco, Brazil)*;
Ming-Dong Wang (Public Health Agency of Canada,
Canada)*; Qian Wang (Xinjiang Medical University,
China)*; Ya Xing Wang (Capital Medical University,
China)*; Ying-Wei Wang (Ministry of Health and
Welfare, Taiwan)*; S Goya Wannamethee (University
College London, UK)*; Nicholas Wareham (University
of Cambridge, UK)*; Niels Wedderkopp (University of
Southern Denmark, Denmark)*; Deepa Weerasekera
(Ministry of Health, New Zealand)*; Peter H Whincup
(St George’s, University of London, UK)*; Kurt
Widhalm (Medical University of Vienna, Austria)*;
Indah S Widyahening (Universitas Indonesia,
Indonesia)*; Andrzej Wiecek (Medical University of
Silesia, Poland)*; Alet H Wijga (National Institute for
Public Health and the Environment, The Netherlands)*;
Rainford J Wilks (The University of the West Indies,
Jamaica)*; Johann Willeit (Medical University of
Innsbruck, Austria)*; Peter Willeit (Medical University
of Innsbruck, Austria; University of Cambridge, UK)*;
Emmanuel A Williams (Komfo Anokye Teaching
Hospital, Ghana)*; Tom Wilsgaard (UiT The Arctic
University of Norway, Norway)*; Bogdan Wojtyniak
(National Institute of Public Health-National Institute
of Hygiene, Poland)*; Roy A Wong-McClure (Caja
Costarricense de Seguro Social, Costa Rica)*; Justin YY
Wong (Ministry of Health, Brunei)*; Tien Yin Wong
(Duke-NUS Medical School, Singapore)*; Jean Woo
(The Chinese University of Hong Kong, China)*; Mark
Woodward (University of New South Wales, Australia;
University of Oxford, UK)*; Aleksander Giwercman
Wu (Lund University, Sweden)*; Frederick C Wu
(University of Manchester, UK)*; Shouling Wu
(Kailuan General Hospital, China)*; Haiquan Xu
(Institute of Food and Nutrition Development of
Ministry of Agriculture, China)*; Weili Yan (Children’s
Hospital of Fudan University, China)*; Xiaoguang
Yang (Chinese Center for Disease Control and
Prevention, China)*; Xingwang Ye (University of
Chinese Academy of Sciences, China)*; Panayiotis K
Yiallouros (University of Cyprus, Cyprus)*; Akihiro
Yoshihara (Niigata University, Japan)*; Novie O
Younger-Coleman (The University of the West Indies,
Jamaica)*; Ahmad Faudzi Yusoff (Ministry of Health
Malaysia, Malaysia)*; Ahmad Ali Zainuddin (Universiti
Teknologi MARA, Malaysia)*; Sabina Zambon
(University of Padova, Italy)*; Antonis Zampelas
(Agricultural University of Athens, Greece)*; Tomasz
Zdrojewski (Medical University of Gdansk, Poland)*;
Yi Zeng (Duke University, USA; Peking University,
China, USA)*; Dong Zhao (Capital Medical University
Beijing An Zhen Hospital, China)*; Wenhua Zhao
(Chinese Center for Disease Control and Prevention,
China)*; Wei Zheng (Vanderbilt University, USA)*;
Yingfeng Zheng (Singapore Eye Research Institute,
Singapore)*; Dan Zhu (Inner Mongolia Medical
University, China)*; Baurzhan Zhussupov (Kazakh
National Medical University, Kazakhstan)*; Esther
Zimmermann (Bispebjerg and Frederiksberg Hospitals,
Denmark)*; Julio Zu~niga Cisneros (Gorgas Memorial
Institute of Public Health, Panama)*
883i International Journal of Epidemiology, 2018, Vol. 47, No. 3
